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While off-label drug use in oncology is an international issue and had significant 
implications for the health care system, the information on the off-label use of the 
targeted agents is currently poorly documented. This may be particularly important as 
more than 30 targeted agents are approved by FDA since 1997. Most of these drugs have 
narrow approved indications with respect to cancer types and stage of the disease and 
they could be used in off-label manner due to their wide anti-cancer activity. Hence, 
investigations are needed to provide a better understanding of off-label use associated 
with targeted therapies considering the reimbursement constraints, high cost, and 
uncertain scientific evidence. Aflibercept which is a potent angiogenesis inhibitor is  
selected as targeted drug candidate for the investigation in this thesis.  
 
While special access programs (SAP) provide a pathway for accessing unregistered and 
investigational drugs for those patients who have limited options available with the 
approved treatments. There is a possibility that drugs obtained under SAP might be used 
differently from approved regulatory recommendations. Off-label drug use under SAP 
program may compromise clinical outcomes and patient safety due to limited evidence 
of efficacy outside trial setting and incomplete information on toxicities risk. It is thus 
important to evaluate whether the targeted therapies are used in off-label manner for 
Asian patients under SAP. 
 
Furthermore, off-label drug use practice is likely indispensable in cancer therapy, 
particularly for patients with limited treatment options. It is thus desirable to establish a 
practice framework for guiding off-label prescribing that have a favourable benefit-risk 
ratio. This will in turn safeguard both practitioners and patients. As oncology 
practitioners play an important role in any clinical practice framework and current 
  
information on their perceptions regarding off-label drug use in oncology in Asia has not 
been studied, it is thus pertinent to hear their views. 
 
Study Objectives 
1. To conduct systematic literature review of off-label use of aflibercept for 
oncology indications 
2. To study the off-label use of aflibercept under SAP in Singapore. 
3. To study the perceptions of oncology practitioners on off-label use in cancer 
therapy. 
Summary of important findings 
The thesis found that none of the off-label use of aflibercept for any indication could be 
recommended for routine practice based on the current scientific evidence. The thesis 
also gave preliminary indication that off-label does exist in SAP and this finding should 
be confirmed in a larger study with adequate sample size. The off-label use of drugs 
under SAP would have its own unique clinical, safety and ethical implications for 
prescribers and patients. Lastly, the thesis provided the data which highlighted the 
concerns expressed by oncology practitioners on off-label prescribing in oncology. This 
certainly demands the formulation of practice framework monitoring off-label use of 
anti-cancer drugs at the institutional level. A research study evaluating the impact of 
practice framework on reducing irrational off-label prescribing and adverse events due to 




1 Introduction  
1.1 Definition of off-label drug use 
The role of the drug regulatory bodies worldwide is to approve a medicine for clinical 
practice based on randomized control trials and strict licensing standards.  They also 
publish prescribing information based on the data of the pivotal trials submitted in 
support of the marketing authorisation applications. Prescribing information (PI) serves 
as a clinical guidance document for practitioners in routine practice population. 
However, this product information is not intended to prevent the practitioners from using 
his or her best medical judgment in the best interest of patients. Indeed, the practice of 
medicine will necessitate the practitioners to use the medicines by drawing a conclusion 
from medical literature and tailor it to individual patient encountered in clinical practice. 
Thus, use of a drug in routine clinical practice might not comply with the prescribing 
information. 
 
Off-label drug use defined as all use of an approved medicine not mentioned in the 
prescribing information regarding therapeutic indication, dosage, route of administration 
or patients population (1, 2). The evidence guiding off-label drug use might vary both in 
quality and consistency. Off-label drug use based on little or no scientific evidence is 
termed as off-evidence drug use (3). For example, prescribing a drug for indication 
outside clinical trial without knowing the results of the clinical trial. Off-label drug use is 
dissimilar from compassionate drug use. Compassionate drug use also known as 
expanded access facilitate the use of investigational therapies to either individual or 
group of patients suffering from chronic, severely debilitating, or deadly illness, without 
a suitable approved treatment accessible and who cannot participate in clinical trials or 
get unlicensed medicines (4). Off-label drug use is further demarcated from unlicensed 
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drug use which means the use of therapeutic entity which has never received any 
regulatory approval for any clinical use in either pediatrics or adult population (5). 
Physicians are generally allowed to prescribe the drug in an off-label manner in most 
regions except country like India where it is illegal (6). Off-label status of a drug could 
vary among different countries due to different timings of marketing authorisation or 
lack of drug approvals for newer indications. 
 
Table 1 Summary of definitions 
Off-label drug use Clinical practice of prescribing medicines outside the terms 
mentioned in the Prescribing Information (PI). 
Unlicensed drug use Drugs which are not subjected to review for their efficacy 
and safety by drug regulatory agencies. 
Investigational 
therapies 
Drugs are being scientifically studied but are yet to be 
approved by the licensing authorities for clinical practice. 
Compassionate use Prescribing newly unapproved agents through individual 
patient use request or expanded access programs (EAPs) to 
treat life-threatening diseases for which there are no 
available treatment options. 
Extemporaneous 
preparations 
It is the procedure of compounding various ingredients to 
formulate an unlicensed medication for a single patient in 






1.2 Prevalence of off-label pharmacotherapy in medical practice 
The off-label use of drugs in routine practice is done principally to address the unmet 
medical need. It is challenging to estimate the exact prevalence of off-label drug use. 
This is due to lack of reliable healthcare databases and difficulty in detecting off-label 
indications in medical records.  In addition, the prescriptions which are inconsistent with 
the terms of the FDA label are not recorded separately by health insurances or other 
national databases (7). On the other hand, pharmaceutical organizations are not required 
to give precise information on their drug sales for off-label uses. In fact, sales associated 
with off-label drug uses may generate additional revenue for them without them 
investing in expensive clinical trials (8).  
 
Off-label use is widespread across almost all different diseases and healthcare settings 
(9). Among all, children are frequently prescribed medication in an off-label manner as 
pharmaceutical companies had not carried out and submitted pediatric clinical trials data 
to regulatory bodies at the time of drug approval. As a result, the pediatrician had no 
option left but to prescribe medicine off-label. One of the largest research study carried 
out in the United States concluded that most pediatric patients were prescribed minimum 
one off-label medicine which also accounted for 40% of total medication expenditures 
(10). Studies have also been published reporting off-label use in several pediatric 
subspecialty services including gastroenterology, cardiology and pain management (11-
13). Recently, there is evidence linking increased risk of adverse drug events with off-
label prescribing in children (14). In the neonates, almost all drugs are administered in 
off-label manner (15). In the adult population, off-label use has been reported across 
various healthcare settings and diseases. Off-label drug prescribing is exceedingly 
widespread across clinical areas like psychotic disorders, dermatology, adult critical 
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care, cardiology, neurology, nephrology and obstetrics (1, 16-18). Based on the 
published literature, it appears that off-label use of drugs is widespread across several 
diseases internationally and is likely to grow in coming years (15, 19). 
 
1.3 Benefit and risk of off-label drug use 
In era of contemporary medicine, off-label drug use has become standard practice in 
some diseases grounded on the scientific evidence and practitioners’ clinical expertise 
(20).  These drugs are provided either to meet a public health requirement not covered by 
an approved licensure or to warrant medicine access to particular patient groups (21). 
From these aspects, off-label drug prescribing is beneficial as it not only improves access 
to valuable medicines to patients but also allows innovation in routine practice 
especially, when approved therapeutic regimens have failed or emerging evidence 
suggest changes in treatment protocols (9).  
 
Instances of off-label prescribing that benefited patients comprise use of aspirin for 
prophylaxis against cardiovascular disease in diabetes, use of tacrolimus as last-hope 
therapy for autoimmune disorders, use of gabapentin as first line treatment for painful 
diabetic neuropathy and use of cisplatin for the off-label indication in cancer of head and 
neck, esophagus, gastric, lung, lymphoma and anal canal (22, 23). In some cases, such as 
use of bevacizumab for curing age-related macular degeneration, off-label drug therapy 
is considered to have the same therapeutic efficacy and is more cost-effective than the 
currently approved drug ranibizumab (24, 25). However, due to a lack of proper 
regulation, off-label drug prescribing has the potential of exposing patients to uncertain 
risks (26). This is mainly due to the fact that off-label drug uses are not systematically 
appraised by regulators, guidelines formulators or even healthcare policymakers. Non-
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evidence based off-label drug use may pose unknown toxicity risk (27, 28). Several 
widely practiced off-label drug uses have also been found to be either harmful or 
ineffective when properly scrutinized (29). For example in a study by Radley et al, 
where 150 million off-label prescriptions were evaluated, they found that 73% of off-
label drug use lacks strong scientific evidence that compromises patient safety or 
represents wasteful medication use (30).  
 
Additionally, other studies have reported off-label drug use as an independent factor 
contributing to the occurrence of adverse drug reactions (31, 32). This is because a drug 
used in off-label setting may exhibit different pharmacodynamic and pharmacokinetic 
profile in the body, thus predicting frequency and severity of side-effects could be very 
challenging.  Another example is the treatment of men who are at a high risk of prostate 
cancer using 5α-reductase inhibitors in an off-label manner to decrease cancer risk as 
suggested by the ASCO guidelines published in 2009 (33). This off-label use was 
however concluded to be dangerous as data from the REDUCE trial indicated an 
augmented risk of a more aggressive form of cancer with dutasteride therapy. This in 
turn prompted a drug safety alert published by FDA in 2011 for this toxicity concern 
(34). Other data that highlighted the risk linked with off-label drug use includes the 
systematic assessments within the post-marketing surveillance programs by the RADAR 
(Research on Adverse Drug events And Reports) working group where that serious and 
unknown ADRs are often found to be occurring due to off-label drug use for which 






1.4 Pharmacovigilance of off-label drug use 
Unfortunately, the present pharmacovigilance and post-market surveillance methods do 
not monitor off-label drug use. Standard monitoring approaches using the FDA’s 
Adverse Event Reporting System (FAERS) do not specifically look for off-label 
indications. Some methods have been proposed using the data mining approach in 
clinical notes or capturing indications during electronic prescribing to enhance 
surveillance of off-label indications (36, 37). Pharmaceutical companies could greatly 
assist in shaping the safety data of off-label drug use. They should as part of the signal 
detection process, evaluate off-label indication by searching for patterns of use and 
safety concerns. As there could be little or no other data in the database or medical 
literature to support off-label drug safety analysis, individual cases become more critical 
in the analysis. These cases should be maintained in the signal list and reported to the 
drug regulatory authorities and other stakeholders if the cases meet expedited reporting 
provisions. Also, it is essential to comprehend that off-label drug safety information 
must be incorporated in Periodic Benefit Risk Evaluation Report (PBRER) and, if 
essential, in risk evaluation and mitigation plan as well as risk management plan.  
 
The off-label drug use without strong evidence base could greatly alter the benefit-risk 
ratio and could be catastrophic for the patients rather than providing any meaningful 
clinical effects. This is especially relevant for off-label use of newly marketed drugs and 
novel off-label use of old drug with limited background information regarding efficacy 
and particularly toxicity data, even if the drug itself has been available in market for 





1.5 Regulatory reforms for off-label drug use 
The regulation pertaining to practice of off-label drug use are not harmonised across the 
world. In the United States, off-label drug use can be legally prescribed but it restricts 
manufacturers from promoting the unapproved use of licensed drugs (38). In 2006, the 
ASCO emphasized the necessity to update and completely apply the ‘standard medical 
compendia’ used by Medicare in the US to cover designated, evidence-based, off-label 
use of oncology drug (39). Off-label prescribing is even legal in Europe but each 
member state has own regulations (40). European Society of Medical Oncology (ESMO) 
has suggested the drug regulatory bodies to take some responsibility for off-label drug 
use. ESMO proposed listing standard off-label indications for anticancer drugs that could 
be approved by the European Medicines Agency (EMEA). This mechanism would not 
resolve the whole problem at once, but it would, at least, streamline the condition and 
improve the physician’s position particularly concerning the question of medical liability 
when challenged with the described contradictions of off-label drug use (41). This might 
facilitate the creation of compendia of oncology drugs, enlisting those off-label uses 
adjudged to be evidence based and legitimate to practice. It could partly ensure 
physician’s freedom to prescribe quality of care and thus prevent legal liabilities.  
 
Off-label drug use is very common in pediatric oncology. Hence, Europe launched 
Paediatric Medicine Regulation in 2007 with an aim to improve pediatric clinical trials 
and medicines but it fails to facilitate an increase of early drug trials and many children 
with advanced malignancies are still denied access to innovative drugs (42). Many 
European countries like Austria, France, Germany, Spain, the UK, and Switzerland 
considered off-label drugs as a problem in the drug supply to patients and took different 
ways to handle the problem so as to moderate its negative effects (43). Many reforms 
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have been suggested in different countries. In Japan, a drug can be licensed for off-label 
indication based on the evaluation of published literatures whereas China had 
recommended a grading mechanism for off-label indications (44, 45). 
 
1.6 Ethical standards for off-label prescribing 
The ethical reasoning for off-label drug use is to offer best possible treatment to patient 
grounded on the sound evidence base. However, the evidence guiding off-label drug 
prescription could differ greatly on the case to case basis (46). Scientists frequently test 
off-label drug use using informal research but in routine practice off-label drug 
prescribing should be based on the proper therapeutic goal and individual patient need 
(20). Professional bodies like American Medical Association and American Cancer 
Society supports off-label drug use and has issued useful guidelines on off-label drug 
prescribing (47, 48). These advisory statements implicitly advocate three main ethical 
considerations pertinent to off-label drug use: (1) Appraisal of most up-to-date evidence 
supporting off-label drug use; (2) gathering data and doing research when there is 
insufficient evidence regarding an off-label use; and (3) Addressing disclosure 
requirement to patients about what prescriber should inform them about off-label status 
of therapy, obtaining verbal or written consent and explaining  probable  benefit, risk and 
economic consequences. 
 
1.7 Off-label drug use: reimbursement issues for cancer treatments 
Off-label drug use has been found to increase the economic burden on cancer patients. 
The total expenditure associated with off-label chemotherapies was reported as US$4.5 
billion and US$2 million in two studies (49, 50). When there is inadequate evidence 
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from trials, it becomes more difficult to determine if there is sufficient value for off-label 
drug use to warrant successful reimbursement (51). Considering cancer treatments are 
expensive, the situation worsens when off-label drugs are not reimbursed and would 
ultimately increase out-of-pocket costs to patients. Many oncologists reported changing 
their therapeutic regimens due to reimbursement constraints resulting in poor medicines 
access to cancer patients (52). In the US, Medicaid would  reimburse off-label drug use 
that is listed in compendia such as the American Hospital Formulary Service’s Drug 
Information and Thomson Healthcare’s Drug Points System (39). Interestingly, few 
managed care establishments and private health insurance plans in the US have refused 
to pay the cost of drugs used in an off-label manner to treat cancer disease stating that 
these clinical uses are “experimental” or “investigational.” 
 
Few countries, such as the United Kingdom limit or reject access to unapproved drugs 
use on the grounds of lack of proven cost-effectiveness. In Sweden, bortezomib and 
trastuzumab were reimbursed by the National Reimbursement System for routine use at 
the choice of concerned medical oncologists, exemplifying their willingness to prescribe 
for off-labelled indications. Sweden along with Finland, permitted reimbursement of 
intravenous cancer drugs provided that they are included in the hospital-based practice 
guidelines formulated by medical oncologists. But these guidelines could vary according 
to the treating cancer centre. For example, the off-label use of bevacizumab for the 
treatment of glioblastoma had different reimbursement coverage across the hospitals in 
Finland and Sweden (53). France recently opted for new French law with an objective to 
warrant safety of drugs and other health care products. This new regulatory mechanism 
called as “Temporary Recommendations for Use” enabled France for provisionally 
overseeing the prescribing of drugs for unapproved indications and subsequent 
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successful reimbursement in clinical practice (54). Japan rejected reimbursement for off-
label drug use while Italy changed its rule to facilitate use and reimbursement of cheaper 
off-label alternative such as bevacizumab in age-related macular degeneration (55, 56). 
 
1.8 Reasons for off-label prescribing in cancer pharmacotherapy 
Once a drug is approved by the regulatory authorities, a particular pattern of off-label 
prescribing is observed in routine practice. Initially, there are individual patients treated 
with off-label drug use by oncologists and later on their clinical outcomes are reported in 
scientific literature in the form of case reports, case series, symposia reports, and small 
cohorts. These publications are deliberated to be “evident” by other prescribers and 
served as guidance for legitimate and more manifested off-label drug use. Eventually, 
this approach might even result in a situation where off-label drug use is accepted as 
standard care such as for several childhood cancers (57). 
 
There are myriad of reasons why off-label drug use is indispensable practice in cancer 
therapy. These reasons are highly diverse and complicated. First, the data included in the 
prescribing information cannot guide clinical care of a diverse range of tumor types and 
patients’ characteristic in routine practice. In routine practice, cancer patients have 
several co-morbidities, contraindications, older age, medical history and drug allergies 
which limit the applicability of the approved regimen. As a result, many anti-cancer 
drugs are prescribed in altered doses, drug combinations, schedule of treatment, route of 
administration and duration of therapy different from FDA approved recommendation.  
Second, the difficulty in conducting Phase III randomized clinical trials for orphan or 
uncommon tumors with sufficient statistical power to measure the significant impact on 
overall survival. For such cases, inadequate evidence from phase II trials may show the 
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benefit of drugs and thus, those drugs may be implemented in clinical practice in an off-
label manner. Third, there is a lag time between encouraging clinical trials findings, 
either published in peer-reviewed journals or reported at scientific symposia, the 
sponsor’s new drug application for FDA review and the subsequent FDA authorization.  
Fourth, pharmaceutical companies are unwilling to apply for supplementary indications 
of previously approved drug in the market due to the expiration of the patent or lack of 
enough financial incentives. Going by the definition, if this medicine is being adopted by 
oncologists after the release of clinical trial results preceding FDA approval, this 
medicine can be considered as off-label drug use based on sound scientific evidence.  
 
Fifth, it is even possible that a drug approved for a cancer with specific gene expression 
is also active in patients having different type of genetic mutation. For example, 
crizotinib approved for anaplastic lymphoma kinase (ALK)-rearranged non-small cell 
lung cancer was found to be efficacious in patients with c-ros oncogene 1 (ROS1) 
oncogene rearrangement (58).  Sixth, medical oncologists managing patients suffering 
with advanced or metastatic stage of disease are willing to try drugs with uncertain 
evidence outside trial as a hope that these off-label drugs may offer prolonged survival 
frequently at the request of their patients (3, 26, 59). Lastly, insufficient prescriber’s 
knowledge of the existing FDA-approved drug labels also contributed to off-label use 
(60). 
 
1.9 Extent of off-label anti-cancer drug use in routine practice 
The use of the chemotherapy outside their recommendations of the prescribing 
information can be defined as off-label drug use for a different tumour or reasons as 
shown in Table 2. In general, they can be broadly classified into four main different 
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types namely [1] Unapproved drug for specific tumour group, [2] Unapproved drug for 
specific stage of disease (neoadjuvant, adjuvant, palliative, curative), [3] Unapproved 
line of treatment, and [4] Modified application of drug (e.g. dose, frequency, 
combination, route of administration). Off-label use of anti-cancer agents is widespread 
in oncology (5, 19, 61). As per the estimate made by NCCN in 2005, 50 to 75% of 
chemotherapies are prescribed for off-label indications in the United States (62). The 
general characteristics of various studies reporting on the extent of off-label 
chemotherapies are described in Tables 3.  
Table 2 Off-label drug use reasons and corresponding examples in oncology.  
No. Off-label reasons Example* 
1 Type or subtype of cancer  Oxaliplatin is indicated for colorectal cancer 
but prescribed in breast cancer. 
 Trastuzumab used in ERBB2-negative instead 
of ERBB2-positive breast cancer. 
 Liposomal doxorubicin is approved for 
metastatic breast cancer in patients with an 
increased cardiovascular risk but is used in 
patients without this risk. 
2 Dose  High dosing of carboplatin in intensive 
chemotherapies instead of the approved dose. 
3 Expression of dosing  Fixed dose of trastuzumab prescribed instead 
of that adjusted for bodyweight. 
4 Drug approved as 
monotherapy but given as 
 Raltitrexed combined with irinotecan in 
metastatic colorectal cancer. 
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combination therapy  Trastuzumab with chemotherapy in pretreated 
metastatic breast cancer. 
5 Drug approved in 
combination but given as 
single agent 
 Single agent bevacizumab administered for 
metastatic colorectal cancer. 
6 Unapproved combination  Trastuzumab is given with vinorelbine instead 
of paclitaxel or docetaxel in untreated 
metastatic breast cancer. 
7 Schedule of administration  Every week instead of every 3 weeks for 
paclitaxel and docetaxel. 
8 Duration of treatment  Trastuzumab is given beyond progression in 
metastatic breast cancer. 
9 Route of administration  Intraperitoneal injection of cisplatin rather 
than intravenous. 
 Subcutaneous administration of alemtuzumab 
instead of intravenous. 
10 Age  Use of adult-approved drugs in children. 
11 Line of treatment  Panitumumab for 1st line of treatment instead 
of pretreated advanced colorectal cancer. 
12 Course of disease  Use of irinotecan for adjuvant therapy rather 
than treatment of advanced colorectal cancer. 
*There might be changes in current off-label status due to subsequent regulatory 






Table 3 Characteristics of the studies assessing prevalence of off-label drug use in 




Drugs Studied Type of 
cancer 
studied 

























RS 9 years 13,347 2,3 75 -- 










RS 8.5 years 2,663 2,3,4 55 13 








RS 35 months 990 1,2,3 29 -- 




-- --  Hospital PS  3 months 985 1,2,3,4 27 32 




-- -- Hospital PS  6 months 1,122 1,2,3,4 41 71 








RS  1 year -- 1,2,3 30 -- 








RS  10 years 37,351 1 -- 33% 










RS 15 years 1,35,608 1 -- 53 




-- -- Hospital PS  6 months -- 1,2 -- -- 













RS  34 months 1,041 3,4 -- 13 




-- -- Hospital PS  3 years 843 1,2,3,4 -- 15 




Temozolomide -- Hospital PS 6 months 831 1,4 48 -- 







Registry RS 2 years 637 1,3,4 -- 62 












-- -- Hospital PS 2 weeks 39 1,4 43 87 









RS 16 months 371 2 -- 7 




-- -- Hospital PS  2 days 644 1,3,4 19 43 
























RS 40 months 1,469 4 -- 22 




-- -- Hospital PS  1 year 1,206 1 7 -- 




-- -- Hospital PS  1 day 130 1,4 18 85 




-- -- Hospital PS  4 weeks 51 1,4 26 100 




-- -- Survey PS  -- -- 1,3 33 56 
*OL: Off-label, RS: Retrospective study, PS: Prospective Study, OL categories:  1) Unapproved drug for specific 
tumour group, 2) Unapproved drug for specific stage of disease (neoadjuvant, adjuvant, palliative, curative), 3) 
Unapproved line of treatment 4) Modified application of drug (e.g. dose, frequency, combination, route of 
administration), SEER: Surveillance, Epidemiology, and End Results. 
 
1.9.1 Studies published in North America 
The first ever exploration on the extent of off-label use in cancer therapy was carried out 
by the General Accounting Office in the United States (52). They found the off-label use 
of anti-cancer drugs to be extensively prevalent and 33% of prescriptions were off-label 
with more than half (56%) of all the cancer patients were prescribed minimum one off-
labelled drug. They also found that off-label drug use depends on patients’ 
characteristics, the therapeutic intent, the stage of cancer and reimbursement policies. As 
the study was designed in the form of the survey with small sample size, the accuracy of 
the true prevalence of off-label use could be different from actual practice.  
 
Subsequently, in a larger study carried out at MD Anderson Cancer Centre using SEER 
database revealed that approximately 35% of distant stage breast cancer patients 
received off-label drugs (77). They also assessed the appropriateness of the off-label 
prescriptions using DRUGDEX classifications and found that 71% of off-label uses were 
without supporting evidence. In another study which assessed chemotherapy prescribing 
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pattern in a military treatment facility in the US, 50% of regimens in outpatients were 
off-label and commonly observed in the adjuvant (49%) and palliative setting (34%) 
(76).  
 
Apart from these, Jonas de Souza et al studied unsupported off-label chemotherapy 
regimens of bevacizumab, cetuximab, capecitabine & panitumumab for the treatment of 
metastatic colon cancer in the United States (50). They evaluated three regimens which 
NCCN guidelines recommended against the use for routine practice. These include - 1) 
bevacizumab use beyond disease progression; 2) capecitabine monotherapy as a salvage 
treatment after failure on a fluoropyrimidine-containing treatment; 3) cetuximab or 
panitumumab after disease progression who has previously received EGFR monoclonal 
antibodies.  They found that 13% of patients (out of 1041 mCRC patients) received any 
one of these off-label treatments without any scientific evidence. These off-label 
regimens were estimated to be costing about US$2 million. Carlos et al using the SEER-
Medicare database found that 53% of 1,35,608 total patients aged above 65 years old 
received at least one off-label prescription (69). Off-label use was common among all 
types of cancers studied and 24% of breast cancer, 86% of non-small lung cancer, 98% 
of small cell lung cancer and 47% of ovarian cancer patients’ received one claim 
containing off-label use.  
 
In another study using same SEER-Medicare databases, Dawn  et al retrospectively 
evaluated off-label use in metastatic cancers patients and found that such practice was 
present in 33% of cases among 37,351 patients reviewed (68). Of those who received 
off-label drugs, 69% of off-label drug use was based on compendia listing.  The mean 
number of off-label claims was 10% and highest among patients with prostate cancer 
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and lowest in colorectal cancer patients. Conti et al studied the off-label use of 10 patent 
protected drugs using  infused outpatients chemotherapy orders of 122 medical oncology 
practices across 35 US states (49). Overall, 30% of chemotherapy orders were off-label 
and 14% of off-label drug use fulfilled the NCCN-supported recommended cancer site. 
But 10% off-label use was not consistent with NCCN recommendations for line of 
treatment and/or cancer stage. The spending on off-label chemotherapeutic regimens 
accounted for US$2 billion for off-label supported by NCCN and US$2.5 billion for off-
label drug use but unsupported by NCCN guidelines.  
 
A study by Kalis et al at a community oncology centre in US assessing oral 
chemotherapy found that off-label drug use amounted to 29% among 990 patients 
receiving  44 different medications (65). Three percent of off-label prescriptions were 
unsupported by NCCN treatment guidelines. Sophie et al studied off-label drug use 
among female breast cancer patients and quality of supporting evidence (64). A total of 
2,663 breast cancer patients received 1,636 (13%) off-label prescriptions representing 
unique 36 off-label cancer therapies. Most off-label use was evidence-based but more 
likely to be related with private health insurance, young age, ethnicity and drugs with 
narrow indication with longer market existence. Off-label use was higher for alkylating 
agents and topoisomerase inhibitors than other class of chemotherapies. Off-label use 
with limited evidence was found with bevacizumab, carboplatin and leuprolide. 
 
Anne et al evaluated prevalence and safety of off-label drug use in older breast cancer 
patients aged above 65 years using SEER-Medicare database in United States (63). A 
total of 13,347 breast cancer patients were treated with 16,127 different treatment 
regimens. Sixty-four percent (10,391) of treatment regimens were off-label/NCCN-
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supported and 11% (1,749) regimens were off-label/NCCN-unsupported with higher 
percent of such drug use in stage III/IV patients and these practices were mainly in the 
form of neoadjuvant and altered adjuvant regimens. The main reason for off-
label/NCCN-unsupported use (76%) was use of drug outside approved stage of cancer 
and/or line of treatment, while drugs not indicated for breast cancer amounted for 19% 
of off-label/NCCN-unsupported use and 1% of total drug use. Hospitalization and 
emergency room visits were substantially higher with patients receiving off-
label/NCCN-unsupported treatment regimens. 
 
1.9.2 Studies published in Europe 
Conroy et al prospectively studied the incidence and nature of off-label and unlicensed 
prescribing in pediatric patients with acute lymphoblastic leukaemia and other cancer 
types (81). They found that 26% and 19% of prescriptions were off-label and unlicensed 
respectively. Among the small sample population, all the pediatric cancer patients 
received at least one off-label drug administration during their course of illness. Van den 
Berg et al using the medication order data from the pediatric oncology ward at a children 
hospital in Netherland found that 43% of prescriptions were off-label and 87% patients 
received at least one off-label/unlicensed use during their hospital stay (57). 
 
A prospective French study which assessed adult ambulatory prescriptions found very 
low proportion of off-label drug use (7%) which might be due to the narrow definition of 
off-label use that was only based on unapproved indication (79). An Italian study done 
over two randomized non-consecutive days over two weeks at 15 oncology centres, 
found that 19% of prescriptions were off-label and most of them were based on the 
published randomized control trials (75). The authors acknowledged their study for small 
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sample size limiting their generalizability of the results and arbitrary classification of 
different off-label uses. Bonifazi et al conducted an assessment of prescribing pattern, 
the incidence of adverse events and survival rate of bevacizumab for the treatment of 
advanced colorectal cancer using Lombardy health care database in Italy (73). They 
found that bevacizumab was prescribed to 62% of patients for an unapproved line of 
treatment, stage of cancer and drug combinations. Approximately 10% of entire sample 
patients suffered fatal toxicities and median overall survival was 21 months with no 
significant difference between gender and age groups.  However, they did not report 
adverse events and survival outcomes separately for patients receiving off-label 
prescriptions.  
 
Tilleul et al prospectively evaluated the off-label use of temozolomide among 831 adult 
patients across 21 French hospitals (72).  A total of 5,982 temozolomide treatment cycles 
were evaluated and 48% of them were off-label.  Global regulatory conformity of 
approved recommendation in terms of treatment duration, drug combination or dose, was 
62% for newly diagnosed glioblastoma patients treated with temozolomide plus 
radiotherapy, 72% for temozolomide maintenance therapy, and 66% for glioblastoma 
and anaplastic astrocytoma in progression/relapse patients. Off-label use based on 
insufficient evidence was found in 5.4% patients. Cioffi et al studied the influence of the 
pharmacist on facilitating evidence-based off-label prescribing in the oncology ward of 
an Italian hospital (71). From an assessment of prescriptions of 843 cancer patients 
spanning over three years of duration, they found that 15% of patients received drugs for 
unapproved indications. Pharmacists were able to reduce off-label uses from 28% to 
10% and also prevented inappropriate drug use cases by suggesting alternative treatment 




Joerger et al prospectively studied the off-label use of systemic chemotherapies 
administered to cancer patients at Swiss hospitals network (66). A total of 1,737 
chemotherapy administrations for 985 patients were evaluated over a period of three 
months. Overall, 32% of patients were prescribed at least one off-label drug, which 
corresponds to a total of 27% of off-label prescriptions. Main reason for off-label use 
was unapproved indication (16%) and modified drug application (10%). Off-label drug 
use was highest in palliative setting (76%). ESMO unsupported off-label drug use was 
rare (6%) but higher for bevacizumab in the treatment of advanced breast and ovarian 
cancer and for lenalidomide in the treatment of non-Hodgkin lymphoma.  
 
1.9.3 Studies published in Australia 
Poole et al conducted a one-day prospective study at Peter MacCallum Cancer Centre in 
Australia which indicated that 18% of prescriptions were off-label for hospitalized 
patients mainly due to unapproved dosing (10%) and unapproved indication (9%) (80). 
The main limitation of the research findings was cross-sectional nature of study, small 
sample size and lack of information regarding patients’ characteristics. In another study, 
Mellor et al aimed to analyse 448 treatment protocols containing 82 different anti-cancer 
drugs that involved off-label and unlicensed prescribing at a specialist oncology centre in 
Australia (70). Overall, 189 treatment protocols (42%) were off-label and 3 (0.7%) were 
unlicensed. All these unapproved treatment protocols were not reimbursed by the 
national health insurance. Out of 189 off-label treatment protocols, 132 (70%) were 
based on treatment guidelines and 21% were based on phase 2 or 3 clinical trials.  In 
addition to this, another Australian study that focused on the off-label use of trastuzumab 
in the treatment of metastatic breast cancer found that 22% of patients received the drug 
 21 
 
in an off-label manner (78). The median duration of the trastuzumab monotherapy as 
well combination therapy was longer than trial conditions.  
 
1.9.4 Studies published in Asia 
A  cross-sectional questionnaire-based study by Gota et al in India revealed that 6 out of 
10 important oncology drugs were prescribed in an off-label manner for different 
indications fully supported by NCCN guidelines with the exception of unapproved use of 
gemcitabine in sarcomas and liver cancer which was based on Phase 2 trials (23).  The 
data from China also revealed that 71% of drugs were used in an off-label manner in 
41% of patients in a sample population of  1122 cancer patients (67). A total of 317 
(28%) of patients received 445 (17%) medical orders which were both off-label and 
unsupported by NCCN guidelines. Off-label use not complying NCCN guidelines was 
higher for unapproved indications (90%) than unapproved drug concentration (8%) and 
unapproved route of administration (2%). Heavily pre-treated and pancreatic cancer 
patients mostly received off-label and off-NCCN chemotherapies.   
 
Based on the published literature, off-label drug use appears to be indispensable practice 
in oncology with high prevalence use across different countries. It is practised across 
almost all types of cancers, stage of cancer and cancer care settings. Off-label drug use 
in hospitalized, as well as ambulatory care patients, was in the same range of 18 to 50% 
prescriptions. The main reasons for off-label drug use were a lack of approved indication 
for specific tumour type, unapproved line of treatment and modified drug application. 
Off-label drug use without support of standard treatment guidelines or drug compendia 
was substantially higher in some of the published studies. Off-label drug use with 
curative intent was in the range of 10 to 41% while that in the adjuvant therapy for early 
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stage cancer and palliative care in the advanced stage of cancer was in the range of 8.5 to 
49% and 34 to 76% respectively. Drugs like bevacizumab, trastuzumab, docetaxel, 
oxaliplatin, capecitabine, gemcitabine, rituximab and cetuximab were frequently 
mentioned in the literature for off-label drug use in different cancer types or lines of 
treatment. There was lack of consensus regarding common definition off-label drug use 
because of the different categories of off-label drug use. In addition to this, off-label 
drug use reported in the literature years back might not be considered off-label in today’s 
scenario due to changes in prescribing information. Hence, the exact prevalence and 














2 A systematic literature review of off-label use of aflibercept for oncology 
indications 
2.1 Introduction 
One of the key mechanism which regulates the formation of the new blood vessel is 
called as ‘Angiogenesis’ and is considered as a driving factor leading to the growth of 
cancerous tissues and metastasis of primary solid tumours (82). This pathway is 
governed by intricate signalling network that includes several interacting proangiogenic 
and anti-angiogenic signals, mainly vascular endothelial growth factor (VEGF), integrins 
and angiopoietins (83, 84). The vascular endothelial growth factor pathway has been 
recognised as one of the cardinal regulators of tumour angiogenesis. VEGF-receptor 
system activation stimulates a complex signalling pathway involving endothelial cell 
development, movement, and survival from the previously existing blood vessels. VEGF 
also facilitates vessel permeability and has been linked with malignant effusions. VEGF 
mobilizes progenitor cells to distant neovascularization sites from bone marrow. Because 
of its continued expression and projected genetic stability, makes targeting VEGF an 
important strategy to arrest solid tumours growth (85, 86). Currently, numerous drug 
antagonists of VEGF pathway, including the VEGF Trap (aflibercept), monoclonal 
antibodies (ramucirumab and bevacizumab) and tyrosine kinase inhibitors (sunitinib, 
sorafenib, cabozantinib, regorafenib, pazopanib, axitinib and vandetanib) have been 
proved clinically efficacious in the treatment of various solid tumours and are approved 
for routine practice across the world (87).  
 
Aflibercept (Zaltrap®) also called as VEGF-Trap, is a recombinant, decoy receptor 
fusion protein, which directly acts on VEGF-A, VEGF-B, and placental growth factor 
(PIGF) to stop angiogenesis. It is a conjugated protein comprising of second and third 
immunoglobulin (Ig) domain of VEGFR receptors 1 and 2 respectively, attached to the 
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stable region (Fc) of humanized IgG1 (88, 89). Aflibercept binds various isoforms of 
VEGF-A, VEGF-B, and PIGF. On the other hand, bevacizumab only binds to VEGF-A. 
The activity of Aflibercept is more inclined towards VEGF-A and their intrinsic 
receptors (89, 90). Aflibercept is of special attention in comparison to other anti-VEGF 
drugs because when exposed they have resulted to escalate PIGF levels which may 
increase VEGF-A expression and signalling and thus activates angiogenesis and 
contribute resistance to angiogenesis therapies.  Hence, a drug like aflibercept which is 
capable of targeting both VEGF and PIGF has the capacity to decrease the likelihood of 
resistance from developing. Moreover, it could be combined with other drugs with 
several targets which could possibly enhance efficacy without causing additional 
toxicities (91).  
 
Aflibercept is currently approved by regulatory bodies for clinical use as combination 
regimen with fluorouracil, irinotecan, and leucovorin (the FOLFIRI regimen) for the 
palliative treatment of metastatic colorectal cancer patients who have progressive disease 
following first-line oxaliplatin-based chemotherapy. The FDA approval decision was 
grounded on the Phase III trial (VELOUR study) in which aflibercept in combination 
with FOLFIRI significantly increased overall survival and progression-free survival by 
1.4 months and 2.1 months respectively in comparison to placebo. Aflibercept received 
USFDA-mandated black-box warning on treatment-related haemorrhage, gastrointestinal 
perforation, and compromised wound healing. The advised dosage of aflibercept is 4 
mg/kg body weight as an intravenous infusion administered every two weeks prior to 
FOLFIRI combination chemotherapy. Treatment with aflibercept is provided until 
progression in disease or intolerable toxicity (92, 93). Although FDA approved for the 
treatment of metastatic colorectal cancer, aflibercept has the capacity to apply direct or 
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continuous VEGF blockade in combination with other treatment modalities. Aflibercept 
provides additional benefit through regression of capillaries, endothelial cell apoptosis, 
decrease in tumour vessel mass and perfusion, blockage of ascites formation and 
decrease in tumour vessel genes. Several physiologic models and tumour xenografts 
have demonstrated promising preclinical results which increased clinical investigations 
for newer off-label therapeutic options in many cancer types (89, 94-101). Multiple 
clinical studies have been performed to investigate the off-label use of aflibercept for 
different oncology conditions, but there is no systematic review literature to date. This 
review attempts to summarize various off-label uses of aflibercept in oncology. 
 
2.2 Method 
Two independent investigators searched for research papers using the scientific 
MEDLINE-PubMed database from inception to July 2016. The search plan comprised of 
the following search terminologies and equivalents: (aflibercept AND cancer). To be 
considered suitable for the systematic review, any study who main objective was to 
evaluate the extent or clinical outcome of the off-label use of aflibercept for oncology 
indications. Pre-clinical research, phase 1 trial, pharmacokinetic or dose ranging studies, 
biomarkers research and meta-analysis were excluded from the review. Full-text articles 
and abstracts with sufficient information were assessed for inclusion. Furthermore, hand-
searching of the bibliographies of potentially eligible articles was also performed to 
identify additional studies. We also searched and included conference abstracts 
presented at American Society Clinical Oncology (ASCO), the Gastrointestinal Cancers 
Symposium and the European Society of Medical Oncology (ESMO) from the year 2010 
to 2016. The quality of randomised controlled studies was appraised by the Jadad 7-item 
scale that comprised of randomization of patients, double-blinding of treatments 
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administered, and withdrawals and/or drop out of recruited patients; the final score was 
described in a range from 0 to 5 (102). Non-randomised control trials were appraised 
using the Methodological Index for Nonrandomized Trials (MINORS) (103). 
Conference abstracts were not scored. 
 
2.3 Results  
The search found a total of 201 publications suitable for the inclusion in the review. For 
the initial screening, 196 papers were evaluated. After examination of the titles, 
abstracts, and full-text publications, 22 studies were included in the review. The general 
characteristics of various studies on the extent and outcomes of off-label use of 
aflibercept are described in Table 4. There were total 22 studies on the off-label use of 
aflibercept mainly done with an aim to assess efficacy and safety for unapproved cancer 
indication. None of the study estimated the prevalence of off-label use of aflibercept in 
routine oncology practice. There were five studies in colorectal cancer (104-108), three 
studies in lung cancer (109-111), six studies in gynaecological cancer (112-117), three 
studies in urological cancers (118-120) and one study for cancer of pancreas, thyroid, 
breast, glioma and melanoma (121-125). The majority of the studies included were phase 
II trials (n=19) (104-108, 110-117, 119, 120, 122-125) and three studies were phase III 
trials (109, 118, 121). All the six randomized studies had Jadad score more than or equal 
to 3 (104, 109, 114, 116, 118, 121). The eleven non-randomized studies have a mean 














































Articles identified by PubMed 
searching (n= 199) 
Studies after removing duplicates 
(n= 201) 
Studies identified after reviewing 
titles and abstracts (n= 196) 
Studies included for 
qualitative synthesis (n= 22) 
 
 
 Original research but not 
entirely focus on off-label use in 
oncology setting (n= 11)  
 Review articles, commentaries, 
guidelines, editorials and case 
reports  (n = 117) 
 Meta-analysis (09) 
 Preclinical research (n=12) 
 Biomarker study (n=06) 
 Phase 1, pharmacokinetic, dose 
ranging studies (n=15) 
 Articles not in English 
(n=04) 
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phase II study 
Aflibercept (4mg/kg) 





PFS: 8.77 vs. 8.48 months  










phase II study  
Aflibercept (4mg/kg) Metastatic 
colorectal cancer 
(n=75) 
PFS: 2 months (bevacizumab-
naïve) and 2.4 months 
(bevacizumab pretreated) 
OS: 10.4 months 

















PFS: 9.3 months  
ORR: 65.9% (29/44 evaluable 
patients) 
Clinically active  -- 











PFS: 4.1 months 
OS: 9.3 months 






clinical activity  
-- 
5 Peter et al 
(108)
 






and radiation  
Stage II/III rectal 
cancer (n=39) 
 
pCR: 25% (4/32 resected 
patients) 
Well tolerated  -- 















PFS: 5.2 vs. 4.1 months  
OS: 10.1 vs. 10.4 months 
ORR: 23.3% (94/404 
evaluable patients) vs. 8.9% 




7 Leighl et al 
(110)
 




Aflibercept (4mg/kg) Lung 
adenocarcinoma 
(n=98) 
PFS: 2.7 months 
OS: 6.2 months 
ORR: 2% 
Well tolerated 14 












ORR: 26% (10/34 evaluable 
patients ) 
due to serious 
toxicity 















PFS: 6.4 months  
OS: 26.6 months 


















For uterine leiomyosarcoma  
TTP: 1.8 months 
For Carcinosarcoma 
TTP : 1.6 months 



















cancer  (n=218) 
For aflibercept (2mg/kg) 
cohort 
PFS 13 weeks, OS: 59 weeks 
ORR: 11.5% 
For aflibercept (4mg/kg) 
cohort 
PFS: 13.1 weeks , OS: 49.3 
weeks 
ORR:11.6% 
Well tolerated 3 












PFS: 2.9 months 
OS: 14.5 months 



















Time to repeat paracentesis: 
55.1 vs. 31.8 days 
Effective but 
use with caution 
due to fatal 
toxicity 
5 








Aflibercept (4mg/kg) Malignant 
ovarian ascites 
(n=16) 
Repeat paracentesis response 
rate: 62.5% 



























Aflibercept (4mg/kg) Metastatic 
Urothelial Cancer 
(n=22) 
PFS: 2.7 months 


















PFS: 8.3 vs. 10.9 weeks 
ORR: 3.1 vs. 1.7% 
Clinically active -- 














PFS: 3.7 vs. 3.7 months 
OS: 6.5 vs. 7.8 months 
Well tolerated 5 












Stabilised disease: 86% (18 
/21) 







20 Sideras et al 
(123)
 




Aflibercept (4mg/kg) Metastatic breast 
cancer (n=21) 
PFS: 2.7 months 












Aflibercept (4mg/kg) Recurrent 
malignant glioma 
(n=58) 
For anaplastic cohort 
PFS: 24 weeks, ORR: 18% 
(7/39) 
For glioblastoma cohort 







22 Tarhini et al 
(125)
 




Aflibercept (4mg/kg) Stage III/IV 
melanoma (n=41) 
PFS: 3.7 months 
OS: 16.3 months 





*PFS: Progression-free survival, OS: Overall Survival, PCR: Pathological complete response, ORR: overall response rate,  TTP: 
Time to progression, OL categories:  1) Unapproved drug for specific tumour group, 2) Unapproved drug for specific stage of disease 
(neoadjuvant, adjuvant, palliative, curative), 3) Unapproved line of treatment 4) Modified application of drug (e.g. dose,frequency, 
combination, route of administration). 
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2.3.1 Colorectal cancer 
Aflibercept blocked the angiogenesis pathway in various preclinical xenograft models of 
human colon cancer. Phase 2-3 trials suggested significant anti-tumour activity of 
aflibercept in mCRC patients progressed after oxaliplatin-based regimen (93, 105, 126-
128).   The current NCCN guideline for colon cancer states that aflibercept is only active 
when prescribed in combination with FOLFIRI in FOLFIRI naïve patients. Aflibercept is 
only recommended in the second-line treatment setting in combination with FOLFIRI or 
irinotecan after disease progression on regimen not comprising of irinotecan (129). 
There is a paucity of evidence to recommend off-label use of aflibercept with FOLFIRI 
in patients who progressed on bevacizumab plus FOLFIRI.  
 
The off-label use of aflibercept as first-line for the treatment of mCRC has been studied 
in two phase II trials (104, 106). The AFFIRM study randomised 236 chemo-naïve 
mCRC patients to receive either mFOLFOX6 plus aflibercept or mFOLFOX6 alone 
(104). The median progression-free survival (PFS) was 8.5 months (95% CI; 7.89-9.92) 
for the aflibercept plus mFOLFOX6 group and 8.8 months (95% CI; 7.62-9.27) for the 
mFOLFOX6 group. The clinical response was observed in 49% (95% CI; 39.7-58.6) and 
46% (95% CI; 36.4-55.7) for the patients treated with and without aflibercept 
respectively. The trial did not have sufficient statistical power to draw a meaningful 
comparison between the two treatment groups. The authors concluded that aflibercept 
does not provide any benefit in terms of PFS but increased serious toxicities risk 
including hypertension, proteinuria, neuropathy, and clotting disorders.  
 
The VELVET trial assessed the safety and efficacy of the OPTIMOX-aflibercept as first-
line treatment of mCRC patients (106). The cohort comprised of 49 patients who 
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fortnightly received six cycles of mFOLFOX7 plus aflibercept as induction therapy. 
Subsequently, patients received fluoropyrimidine (5FU or capecitabine) plus aflibercept 
maintenance therapy till disease progression or toxicity. The median PFS was 9.3 
months (95% CI; 8.7-12.6) and the objective response rate was 59.2% (N = 29/49). The 
common grade 3-4 adverse events were hypertension (23%), fatigue (12%), neuropathy 
(10%) and neutropenia (10%). The investigators concluded that OPTIMOX-aflibercept 
could be a potential treatment regimen for chemo-naïve mCRC patients and 
recommended additional study to confirm the findings in a larger population.  
 
Tang et al carried out a phase 2 trial evaluating the clinical activity of aflibercept as 
single agent in refractory metastatic colorectal cancer patients (105). There were two 
groups in the entire cohort of seventy-five patients; bevacizumab-naive (n = 24) and 
previous bevacizumab (n = 51). The median PFS was 2 months (95% CI; 1.7-8.6) in 
bevacizumab-naïve and 2.4 months (95% CI; 1.9-3.7) in the previous bevacizumab 
group. Median overall survival (OS) was 10.4 months (95% CI; 7.6-15.5) and 8.5 
months (95% CI; 6.2-10.6) respectively. The study concluded that single-agent 
aflibercept cannot be recommended due to limited clinical activity and previous 
bevacizumab has no role on efficacy. In another study, a novel combination regimen of 
aflibercept plus capecitabine was evaluated by a phase 1-2 trial in a cohort of 47 patients 
with mCRC with chemotherapy refractory disease (107). The median PFS was 4.1 
months (95% CI; 2.3-4.8), median OS was 9.3 months (95% CI; 6.2–N/A) and the 
response rate was 6% in 35 evaluable patients. The authors determined that the clinical 




Aflibercept could be considered to be given in combination with anti-VEGF monoclonal 
antibodies. But at present, there is not data supporting the use of aflibercept as 
combination therapy with bevacizumab, cetuximab or panitumumab in an off-label 
manner (129). The role of aflibercept in combination with 5-fluorouracil and radiation as 
potential neo-adjuvant therapy for stage II/III rectal cancer patients was studied in a 
phase 2 trial (108). A total of thirty-nine patients participated in the study which has 
pathological complete response rate (pCR) as the primary endpoint and disease-free 
survival (DFS), sphincter preservation (SP) rate and overall survival (OS) as secondary 
efficacy endpoints. A total of 32 patients were resected, 8 (25%) patients attained pCR, 
and the pathologic partial response was detected in 24 (75%) patients: 9 macroscopic, 15 
microscopic). The sphincter preservation rate was 72%; 31 (97%) patients had R0 
resection. Median OS and DFS were not achieved at the time point of data collection. 
 
2.3.2 Lung cancer 
VEGF pathway is important in the growth and progression of lung cancer as 
demonstrated in several pre-clinical tumour xenograft models. There are drugs including 
bevacizumab, sunitinib, and sorafenib which have shown significant angiogenesis 
inhibition either as a single agent or combination chemotherapy regimens (130, 131). A 
phase 2 trial was designed to study efficacy and safety of single-agent aflibercept in 
patients with platinum and erlotinib-resistant lung adenocarcinoma (110). A total of 98 
patients were recruited, the median PFS was 2.7 months (95% CI; 2.2-3.4), median OS 
was 6.2 months (95% CI; 4.8-11.4) and the overall response rate by intent-to-treat 
approach was 2% (95% CI; 0.2-7.2). The common grades 3-4 adverse events were 
proteinuria, hypertension, and dyspnoea. The authors concluded that aflibercept as single 
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agent has limited clinical activity in heavily pretreated lung adenocarcinoma patients but 
well-tolerated with no unpredicted toxicities. 
 
The international VITAL trial evaluated the efficacy of aflibercept plus docetaxel versus 
docetaxel monotherapy in 913 patients with metastatic non-squamous NSCLC 
progressed to platinum-based regimen (109). Aflibercept did not have any important 
impact on the overall survival. The median OS was 10.1 months (95% CI; 9.2 - 11.6) for 
aflibercept plus docetaxel and 10.4 months (95% CI; 9.2 - 11.9) for docetaxel alone. But 
the PFS appeared to be longer with aflibercept arm. The median PFS was 5.2 months 
(95% CI; 4.4 - 5.6) for aflibercept plus docetaxel and 4.1 months (95% CI; 3.5 - 4.3) for 
docetaxel monotherapy. However, aflibercept increased the risk of grade 3-4 adverse 
events including fatigue, neutropenia, stomatitis, and hypertension. 
 
A phase 2 trial evaluated the efficacy and safety of topotecan plus aflibercept versus 
topotecan plus placebo in extensive stage small-cell lung cancer patients previously 
treated with platinum-based regimen. Aflibercept combination regimen showed better 3-
month PFS (27% v 10%; P=0.02) but the toxicity was increased. OS was not 
considerably enhanced in both groups. A phase 2 trial was designed to evaluate safety 
and efficacy of aflibercept plus cisplatin and pemetrexed in patients with previously 
untreated metastatic non-squamous NSCLC (111). The study was reported median PFS 
of 5 months and ORR was 26% in 38 evaluable patients. But the study was later 
terminated because of three confirmed and two suspected cases of reversible posterior 




2.3.3 Gynaecological cancers 
Increased expression of the VEGF levels has been linked with disease progression and 
poor prognosis in several gynaecological malignancies and endometrial sarcomas 
including carcinosarcoma and leiomyosarcoma (95, 127, 132-135). The efficacy and 
safety of aflibercept plus docetaxel was assessed by a Phase 1-2 trial in patients with 
recurrent ovarian, primary peritoneal, or fallopian tube cancer (113). The ORR was 
confirmed in 25 (54%) of 46 patients (95% CI; 39-69).  The median PFS and OS was 6·4 
months (95% CI; 5·1-10·3) and 26·6 months (95% CI; 13·1-N/A) respectively. The 
investigators concluded that aflibercept plus docetaxel appeared to be safe and clinically 
active in patients with recurrent ovarian cancer and strongly suggested that this 
combination could be clinically developed further into a worthwhile option for this type 
of patients. 
 
A multi-centre phase 2 trial was undertaken to assess safety and efficacy of aflibercept 
monotherapy in patients with gynaecological soft tissue sarcoma (112). A total of 41 
women with uterine leiomyosarcoma and 22 women with carcinosarcoma (19 uterine, 3 
ovarian) participated in the study. In the leiomyosarcoma group, 11 (27%) women had 
stabilised disease with no apparent objective response seen. The 6 month PFS was 17%, 
with a median time to progression (TTP) of 1.8 months (95% CI; 1.6-2.1). In the 
carcinosarcoma group, 2 (9%) patients had SD and median TTP was 1.6 months 
(95%CI; 1.1-1.7) with no objective responses observed in the group. Aflibercept showed 
modest clinical activity in women with uterine leiomyosarcoma and negligible activity in 
women with carcinosarcoma. Tew et al evaluated the efficacy and safety of aflibercept at 
2 different doses (2 mg/kg and 4 mg/kg) in patients with recurrent, platinum-resistant 
ovarian, peritoneal, or fallopian tube cancer who disease progressed after receiving 
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topotecan and/or pegylated liposomal doxorubicin (114). The median PFS was 13 weeks 
(95% CI; 11.7-16.7) and 13.3 weeks (95% CI; 12-18.9] in 2mg/kg (n=106) and 4mg/kg 
(n=109) cohort respectively. The median OS was 59 weeks (95% CI; 41.6-84.1) and 
49.3 weeks (95% CI; 37.4-62.7) respectively. The response rate was similar in both 
cohorts. The authors concluded that aflibercept at both doses did not reach the primary 
endpoints.  
 
A Phase 2 trial assessed safety and efficacy of single-agent aflibercept for the treatment 
of recurrent or persistent endometrial cancer (115). Among 44 patients recruited, the 
median PFS was 2.9 months (90% CI; 2.1-6.21) and median OS was 14.5 months (90% 
CI; 9.86-20.44 months). Although study met the pre-trial efficacy parameters, significant 
toxicities concerning cardiovascular, constitutional, metabolic haemorrhage were 
observed. A phase 2 trial showed that single-agent aflibercept reduced the need to repeat 
paracentesis in 55 patients suffering from malignant ascites in advanced ovarian cancer 
(116). The median paracentesis-free survival was 42 days (95% CI: 27 – 60) with 
aflibercept and 18 days (11 - 25) with placebo. In another phase 2 trial, 10 out of 16 
enrolled patients with advanced epithelial ovarian cancer and symptomatic malignant 
ascites attained a response; the  repeat paracentesis response rate of 62.5% (95% CI; 
35.4-84.8) (117). The median PFS was 59.5 days (95% CI; 41-83). Aflibercept was 
found to be active against malignant ascites. 
 
2.3.4 Urologic cancers 
Aflibercept has been evaluated and is active either alone or with chemotherapy in 
preclinical models of prostate, renal cell and urothelial carcinoma (136-138). A phase 3 
trial called ‘VENICE study’ compared aflibercept plus docetaxel and prednisolone 
versus placebo plus docetaxel and prednisolone in chemotherapy-naïve men with 
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metastatic castrate-resistant prostate cancer (118). Among a total of 1224 patients 
participated, the median PFS was 6·9 months (95% CI; 6·2–7·4) with aflibercept and 6·2 
months (95% CI; 5·6-6·9) with the standard therapy. The median OS was 22·1 months 
(95% CI; 20·3-24·1) in the aflibercept group and 21·2 months (95% CI; 19·6–23·8) with 
standard therapy. There was a higher incidence of grade 3-4 gastrointestinal disorders, 
fatigue, hypertension, and infections. In conclusion, aflibercept did not result in longer 
overall survival but increased the incidence of fatal toxicities.  
 
A single-agent aflibercept phase 2 trial in patients with metastatic urothelial cancer 
previously treated with platinum-based regimen found that aflibercept was well-tolerated 
but had limited clinical activity in this group of patients (119). Among 22 patients 
enrolled, only patients reported partial response and the median PFS was 2.79 months 
(95% CI; 1.74-3.88). A phase 2 trial assessed clinical activity of aflibercept at two 
different doses (1mg/kg and 4 mg/kg) in patients with clear cell metastatic renal 
carcinoma (120). A total of 59 and 35 patients were enrolled in 4 mg and 1 mg dose 
cohorts respectively. The median PFS was 10.9 weeks (90%CI; 8.7-15.4) and 8.3 weeks 
(90%CI; 7.9-9.6) in 4 mg and 1 mg dose cohort respectively. The authors concluded that 
aflibercept was active in clear cell renal carcinoma and worthy of further investigations. 
 
 
2.3.5 Endocrine cancers 
Pre-clinical research had suggested that targeting VEGF reduced tumour development 
and progression in thyroid and pancreatic cell lines (96, 139). A phase 3 trial assessed 
whether adding aflibercept to gemcitabine therapy improved overall survival in 
metastatic pancreatic cancer patients (121). The study was stopped prematurely as there 
was not significant improvement in overall survival with the addition of aflibercept. 
Based on the data of 546 patients at study cessation, the median OS and median PFS was 
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7.8 months (95% CI; 6.8-8.6) and 3.7 months (95% CI; 3.5-4.6) respectively which was 
non-superior than the placebo group.  
 
A phase 2 trial studied safety and efficacy of aflibercept in patients with progressive, 
RAI-refractory/fluorodeoxyglucose (18-F)-avid, recurrent/metastatic, non-medullary, 
nonanaplastic thyroid cancer (122). Among 21 patients recruited, eighteen patients 
achieved stabilised disease and none of the patients has a partial or complete response. 
10 out of 18 patients with stable disease continued for more than 6 months, 3 patients for 
more than 12 months and the median duration of stabilised disease on aflibercept was 
178 days. The investigators concluded that aflibercept was not active in advanced 
thyroid cancer but durable disease stabilisation was common and adverse events were 
manageable. 
 
2.3.6 Breast cancer 
Aflibercept decreased the levels of VEGF secreted from both murine and human breast 
cancer cells and efficiently blocked VEGF-induced tyrosine phosphorylation of 
VEGFR2. Aflibercept as a single agent significantly reduced tumour microvessel 
density, tumour vasculature, cell proliferation and tumour growth of BT474 human 
breast cancer xenografts. Aflibercept reduced levels of both human VEGF and PlGF 
protein in-vivo (140). However, a phase 2 trial assessing the efficacy and safety of 
single-agent aflibercept failed to meet the expected efficacy goals in previously treated 
21 metastatic breast cancer patients (123). At the time of study termination, median PFS 
and median OS was reported as 2.7 months (95% CI; 1.8-5) and 12.7 months (95% CI; 




2.3.7 Glioblastoma  
Based on the promising results of aflibercept in preclinical glioma models, a phase 2 trial 
assessed its efficacy and safety in patients with recurrent malignant glioblastoma and 
anaplastic glioma (124, 141). The median PFS for patients with anaplastic glioma was 
24 weeks (95% CI; 5-31) and 12 weeks (95% CI; 8-16) for glioblastoma patients. 
Aflibercept showed negligible evidence of activity in glioma and the trial was 
unsuccessful to meet the primary endpoints.  
 
2.3.8 Melanoma 
Aflibercept demonstrated to be potent to block angiogenesis and tumour shrinkage in 
pre-clinical melanoma model (142). Based on this, a multicentre phase 2 trial evaluated 
efficacy and safety of single-agent aflibercept in 41 patients with stage 3-4 melanoma of 
cutaneous and uveal origin (125). The median OS and PFS were 16.3 months (95% CI; 
9.2-N/A) and 3.7 months (95% CI; 2.8-6.8) respectively. The partial response rate in 40 
evaluable patients was 7.5% (95% CI; 2-20) and 50% patients have a 4 month or longer 
PFS. Aflibercept showed a promising response in metastatic melanoma of cutaneous or 
uveal origin that warranted further investigations either as single-agent aflibercept or in 
combination with other chemotherapy.  
 
2.4 Discussion  
The systematic literature review gave a summary of emerging evidence regarding the 
various off-label use of VEGF-targeting recombinant fusion protein aflibercept in cancer 
treatment. This study was conducted to generate data regarding the off-label use of 
newer targeted anti-cancer agents with aflibercept chosen as a prototype study drug. The 
major finding of this review revealed that aflibercept has been clinically assessed for 
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different off-label use but currently none of the off-label use can be recommended for 
routine practice either as a single agent or in combination chemotherapy. This is due to 
lack of efficacy, increased risk of toxicity or insufficient scientific evidence. The role of 
aflibercept for clinical use in advanced carcinoid and esophagogastric cancer is presently 
under investigation (143, 144).   
 
The promising result of inhibiting angiogenesis in cancer animal models was clinically 
proven only for second-line treatment of colorectal cancer which has obtained FDA 
approval. However, this was not observed for other solid tumours causing contrasting 
findings in the pre-clinical research and human clinical trials. There are few possible 
explanations as to why angiogenesis inhibition using aflibercept failed to deliver in 
clinical trials, particularly the high rate of toxicity observed in patients which frequently 
led to treatment discontinuation and poor patient compliance (104, 105, 109, 111, 115-
117, 119, 124, 125). One reason could be the impact of narrow patient selection criteria 
which could not provide sufficient population heterogeneity (109, 110, 114, 121, 123). 
Another reason is that for some malignancies investigated including breast and prostate 
which are less aggressive, no impact of treatment arm on cancer progression or survival 
was observed given the short duration of follow-up (118, 123). Patient cross-over and 
impact of previous treatment exposure could also act as a potential confounder. All these 
factors can influence the clinical response and statistically significant survival benefits 
for the off-label use of aflibercept in these tumours. 
 
Some scientists have argued that a problem exists with angiogenesis inhibition as an 
approach for anticancer treatment since in several clinical trials angiogenesis inhibitors 
failed despite encouraging pre-clinical results (145).  One possible explanation is that 
 41 
 
while anti-angiogenesis compounds display tumour regression property, they also have 
an intrinsic property to induce tumour resistance. Tumours exposed to anti-angiogenic 
drugs acquire phenotypic resistance due to VEGF-independent vascular regrowth 
utilising pro-angiogenic ligands of fibroblast growth factor-2 (FGF2) (146). Another fact 
observed with anti-VEGF therapies is the aggressive metastatic tumour growth and 
invasiveness following short exposure to treatment (147, 148).  In addition to this, 
preclinical animal models for studies in angiogenesis inhibition use fast growing 
transplantable mouse tumours or human tumour xenografts which are generally grown as 
solid, localized tumours in subcutaneous tissues. This undoubtedly exaggerates the anti-
tumour effects using anti-angiogenic agents. In such preclinical models, distant 
metastatic are not the focus of treatment and anti-angiogenic effect of study drug could 
be different at such sites because of the unique vasculature of tumour mass (149, 150). 
Moreover, the transplantable tumour models comprise of a high proportion of immature 
new vessels which are more susceptible to escalated anti-angiogenic effects. Thus, the 
significant antitumour effects observed in pre-clinical models might not be observed 
during the clinical research. 
 
The major limitation of the review is the variability in quality as well as the quantity of 
evidence assessing safety and efficacy of the off-label use of aflibercept. This makes 
recommending any off-label use for routine practice extremely difficult or impossible. In 
the present review, a wide array of data presented in randomized double-blind controlled 
trials, non-randomised controlled trials, single arm studies and conference abstracts were 
considered for evidence appraisal to study the off-label use of aflibercept. Many of the 
controlled trials included in the review were of low quality due to lack of randomization, 
blinding, inadequate control arm and sample size in the study design. This may raise the 
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question on the quality of evidence and its reliability for informing clinical decisions and 
other relevant stakeholders. But for certain cancers, limited evidence could be reasonable 
for off-label prescribing. For treating rare tumours, this could be standard oncology 
practice. In France, a registry of 249 soft tissue sarcoma patients treated them with 
targeted therapies including several tyrosine kinase inhibitors based on the evidence 
published as conference abstracts and biological hypothesis (151). In cancer setting, 
what constitutes ‘good evidence’ would be considerably lenient as providers often rely 
on data derived from low-quality studies or gray literature. A study estimated that almost 
50% of the conference abstracts on studies regarding new oncology drugs remained 
unpublished (152).  
2.5 Conclusion 
Aflibercept has the ability to bind with all isomers of VEGF-A as well as to VEGF-B 
and PIGF that are critical in angiogenesis pathway. Pre-clinical and clinical research has 
delivered evidence that support angiogenesis inhibition effects resulting in meaningful 
tumour shrinkage and statistically significant survival benefits with manageable 
toxicities.  However, this is only true for metastatic colorectal cancer when aflibercept is 
used in accordance with FDA approved indication. Currently, the off-label use of 
aflibercept in indications including prostate, breast, renal, urothelial, pancreatic, 
melanoma, glioblastoma, ovarian and lung cancer is not recommended for clinical 
practice. All these off-label uses are considered as ‘investigational’ unless good evidence 
supporting such use is further accrued. Also, the role of aflibercept in other solid 
tumours is not yet successful might be due to activation of resistance pathway or other 
mechanisms not applicable to anti-angiogenesis therapy. The identification of predictive 
biomarkers which can help identify patients who are most suited for aflibercept based 
therapy is also required. 
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3 Off-label prescribing of aflibercept under special access program in Singapore  
 
3.1 Introduction 
The use of medicines approved by a country’s regulatory authority constitutes an 
important part of the quality of care and patient safety agenda. However in routine 
clinical practice, the physician may select a drug that have yet received formal marketing 
authorisation for the patient’s particular disease but has relevant scientific evidence 
guiding its use by the patient. Hence, regulatory bodies in many countries have created 
special access program (SAP) to provide medicines with a good balance of benefit and 
risk and are yet to complete formal licensing procedures (153, 154).  
 
SAPs permit patients to get drugs that lack formal regulatory approval for commercial 
use. SAPs have several forms in different countries mainly called as special access, 
compassionate use, expanded access or named patients assistance programs (155). These 
programs are created to facilitate drug access on the basis of compassion and not meant 
to undermine clinical trial enrollment and drug development process (156). In Singapore, 
this program is availed on named patient basis by the Health Sciences Authority (HSA)  
(157). The approval for unregistered drug product must be obtained from the 
Therapeutic Product Branch of HSA. The physician must apply to HSA on a named 
patient basis through a separate application form and must contain information of the 
medicinal product to be imported for use and details of the importer, as well as the 
prescriber responsible. The medicinal product must be available within 6 months of 
application otherwise stated and prescribing physician must keep a proper record of its 
supply and use. The advantages of this program are that it may be used to provide 
investigational drugs as “last hope” for patients with exhausted lines of treatments and 
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for orphan indications (158). This program also enables access to drugs when there is no 
incentive for the pharmaceutical company to seek local registration. Many countries 
mandate adverse event reporting for drugs used under the SAPs but currently there is no 
regulatory requirement for reporting efficacy and safety data for such drugs in Singapore 
(157).  
 
The drugs provided by pharmaceutical companies under SAP are generally free of any 
cost involved. However, there are concerns expressed that the drugs used as expanded 
access may lead to inappropriate drug use. This could be mainly in the form of off-label 
drug use which is sometimes also termed as ‘off-protocol therapies’ in this particular 
setting (159). In view of the accelerated drug approval process and  the significant lag 
time between USFDA/EMA and HSA approvals, it is foreseeable that the use of SAPs 
may increase in the future. Therefore, it is timely to examine the use of drugs under the 
SAPs so that greater clarification can be provided on the appropriateness of their use in 
the local population. This may in turn provide important information that may guide 
such practices locally. Also, it is argued that such drug use outside trial condition and 
that too with incomplete information when the trial is still being conducted might 
jeopardize the patient's safety (160). Hence, we conducted an exploratory descriptive 
study reporting off-label use and clinical outcomes of aflibercept under SAP at a major 
public cancer center in Singapore. Aflibercept was approved by USFDA in 2012, and 
HSA in 2014. Pending local registration in Singapore, Aflibercept was available under 
named patient assistance program for treatment of metastatic colorectal cancer which 





3.2 Methods  
3.2.1 Study design 
We retrospectively reviewed unregistered drug application forms from January 2012 to 
December 2014 submitted to HSA requesting aflibercept on the basis of expanded access 
program at NCCS. We consecutively included all the cancer patients who received 
aflibercept without any specific exclusion criteria. The study was approved by the 
Singhealth ethical review board.  The requirement of informed consent was waived for 
this study. The primary aim of the study was to report any off-label use associated with 
aflibercept use in cancer patients. The secondary objective was to report efficacy and 
safety of aflibercept under SAP for the indicated use. Off-label use was assessed for 
indication, line of treatment and dose. For prescribing information, both USFDA and 
HSA labels were reviewed. 
 
3.2.2 Data collection  
Based on the information gathered from the HSA application forms, two oncology 
pharmacists retrieved medical records of adult cancer patients who received aflibercept 
under expanded access use with palliative intent from the NCCS electronic database. 
The information on patient baseline characteristics such as age, gender and ethnicity 
were extracted. Clinical information including the primary site of cancer, stage of 
cancer, Eastern Cooperative Oncology Group (ECOG) performance, lines of treatment 
received, indication, corresponding drug response and toxicities were also extracted from 
the patients’ medical records into the study data collection form (Appendix II).  
3.2.3 Statistical analysis 
Baseline characteristics and toxicity data were evaluated by descriptive statistics. 
Objective clinical responders were patients who achieved complete response (CR) or 
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partial response (PR). Disease control was achieved in patients with CR, PR, or stable 
disease (SD). All the outcomes were documented as reported by the physicians in the 
medical records based on the Response Evaluation Criteria In Solid Tumors (RECIST) 
criteria (161). Progression-free survival (PFS) was measured from the start of aflibercept 
therapy to the date of an event, defined as the first documented progression under 
treatment or death because of any reason under treatment. Patients who did not have any 
event were censored during the course of treatment and in cases of premature treatment 
cessation, before the end of follow-up or at the date of the last contact still under 
treatment. Overall survival (OS) was defined as the period between the start of 
aflibercept therapy till documented event of death or censored at the date of the last 
contact for patients who are alive. PFS and OS were measured using the Kaplan-Meier 
method and reported as medians with corresponding two-sided 95% confidence intervals 
(CIs). Safety assessment was based on the incidence and severity of toxicities, graded 
according to the Common Terminology Criteria for Adverse Events (CTCEA) criteria. 




3.3.1 Patient characteristics 
From January 2012 to December 2014, 22 patients at NCCS were screened and got 
approval from HSA to receive aflibercept under SAP. Two patients never received the 
drug leaving a total of 20 patients receiving courses of aflibercept therapy. Majority of 
patients (40%) received 1 to 4 cycles of chemotherapy, followed by patients (35%) 
receiving more than 10 chemotherapy cycles and rest of patients (25%) received 5 to 10 
chemotherapy cycles before starting aflibercept. The patients’ characteristics are 
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presented in Table 5. The population consisted predominantly of Chinese patients (90%) 
and the mean age was 58 years old. Most of the patients (90%) had ECOG status of 0 or 
1. All the patients received aflibercept with palliative intent. Most patients (75%) were 
metastatic at diagnosis and had 3 or more distant metastatic sites at the start of 
aflibercept chemotherapy. The common sites for distant metastasis were peritoneum 
(60%), liver (55%) and lung (55%).   
 
Table 5 Patients Characteristics (N=20). 
 













Age at diagnosis (years) 
 Mean + SD  
 
58 +12  
Primary tumour localization 








 KRAS-wild type 
 KRAS-mutated 
 KRAS-unknown 





































ECOG status at the start of aflibercept use 
 0 
 1 





Previous Radiotherapy   09 (45) 
Previous Surgery 11 (55) 
Previous Chemotherapy* 
 Adjuvant XELODA 
 Adjuvant XELOX 
 XELOX 
 XELOX plus Bevacizumab 
 XELOX plus Cetuximab 
 FOLFOX 















Median  follow-up time from diagnosis  25 months  
*For the treatment of metastatic colorectal cancer unless stated. 
 
3.3.2 Off-label use of aflibercept  
All the patients received aflibercept for the palliative treatment of metastatic colorectal 
cancer which is an FDA approved indication. Aflibercept was given in combination with 
folfiri (irinotecan plus folinic acid and 5-fluorouracil). It was administered at a dose of 4 
mg per kg body weight as intravenous infusion for 1 hour every 2 weeks.  All the 
patients on average received six cycles of aflibercept. Most of the patients (85%) 
received oxaliplatin containing regimen. Off-label use of aflibercept was found in 5 
patients (25%) among the entire cohort. Off-label use was due to prescription of 
aflibercept plus folfiri for unapproved line of treatment (25%). One patient received 
XELIRI (irinotecan and capecitabine combination) and other patient received XELODA 
(capecitabine) as second-line treatment before receiving aflibercept in the third-line 





Table 6 Information on Aflibercept usage under SAP (N=20). 
Indication 
 Treatment of metastatic colorectal cancer 
 
20 (100) 





 4 mg per kg 
 
20 (100) 
Previous oxaliplatin containing regimen 17 (85) 
Modification in FOLFIRI due to toxicity 09 (45) 
Average number of aflibercept treatment cycles 
 Median (Range) 
 
06 (1-26) 
Off-label use for unapproved line of treatment 
 Third-line treatment setting  




3.3.3 Efficacy of aflibercept therapy 
For the entire sample population, two patients (10%) achieved partial response, ten 
patients (50%) achieved stabilised disease (SD) and disease control rate was (DCR) was 
60% (n=12). None of the patient achieved complete response. Carcinoembryonic 
antigen was normalised (< 3ng/ml) in three patients following treatment with aflibercept. 
The median follow-up from diagnosis was 25 months. As shown in Figure 4, the median 
PFS for the whole group was 5.9 months (95% CI; 5.7- 6.4) and median OS was 15 
months (95% CI; 10.9 - 19). The main reason for treatment discontinuation was 
progression in disease status (75%). 
         
         
 




3.3.4 Toxicities related to aflibercept therapy 
The toxicity due to aflibercept and folfiri combination regimen is shown in Table 7. 
Grade 1-2 toxicities were experienced by 50% of the patients and grade 3-4 adverse 
events were encountered in 5% of total patients. The common toxicity of any grade was 
nausea, fatigue and neutropenia. During the treatment, febrile neutropenia and 
proteinuria were the only serious toxicity reported among the two patients. There was no 
case of treatment-related death. 
Table 7 Toxicities and laboratory abnormalities due to aflibercept plus folfiri 
combination therapy. 










Neutropenia 08 (40) 05 (25) 03 (15) 00 (00) 
Febrile neutropenia 04 (20) 02 (10) 01 (05) 01 (05) 
Lymphopenia 05 (25) 05 (25) 00 (00) 00 (00) 
Thrombocytopenia 02 (10) 02 (10) 00 (00) 00 (00) 
Gastrointestinal Mucositis 04 (20) 04 (20) 00 (00) 00 (00) 
Anal Fistula 01 (05) 01 (05) 00 (00) 00 (00) 
Stomatitis 02 (10) 02 (10) 00 (00) 00 (00) 
Nausea 10 (50) 10 (50) 00 (00) 00 (00) 
Constipation 03 (15) 03 (15) 00 (00) 00 (00) 
Cardiovascular 
Hypertension 02 (03) 01 (05) 01 (05) 00 (00) 






03 (15) 03 (15) 00 (00) 00 (00) 
Connective tissues Arthralgia 01 (05) 01 (05) 00 (00) 00 (00) 
Nervous system Peripheral Neuropathy 04 (20) 04 (20) 00 (00) 00 (00) 
Paresthesia 05 (25) 05 (25) 00 (00) 00 (00) 
Metabolism and 
nutrition disorders 
ALT increased 03 (15) 03 (15) 00 (00) 00 (00) 
AST increased 04 (20) 04 (20) 00 (00) 00 (00) 
Weight loss 04 (20) 04 (20) 00 (00) 00 (00) 
Loss of appetite 05 (25) 05 (25) 00 (00) 00 (00) 
Proteinuria 01 (05) 00 (00) 00 (00) 01 (05) 
Lymphatic  Peripheral edema 01 (05) 01 (05) 00 (00) 00 (00) 
Dermatology  Alopecia 01 (05) 01 (05) 00 (00) 00 (00) 
Skin reactions 04 (20) 04 (20) 00 (00) 00 (00) 
General symptoms Fever  03 (15) 03 (15) 00 (00) 00 (00) 
Fatigue 07 (35) 05 (25) 02 (10) 00 (00) 
*below are described the numbers and percentages of patients with at least one toxicity of each grade. (Patient could 







The present study for the first time provided evidence regarding the existence of off-
label prescribing in cohort of patients receiving therapy under SAP in an Asian oncology 
centre. Aflibercept which is a potent angiogenesis inhibitor was found to be prescribed in 
off-label manner among 25% of all patients. The use of drugs in an off-label manner 
under SAP implies that cost and accessibility issues impact the drug use practices. The 
drug was generally well-tolerated with acceptable toxicity profile. The aflibercept 
treatment showed reasonable efficacy in terms of PFS and OS among the Singaporean 
patients. 
 
The main reason for off-label use of aflibercept was unapproved line of treatment as 
first-line and third-line treatment settings. The use of aflibercept in first-line setting is 
not recommended as the AFFIRM trial found that aflibercept did not improve the 
survival but led to increased toxicities (104).  There is no data supporting the use of 
aflibercept in the third-line treatment setting and beyond.  One patient in this study 
cohort was prescribed aflibercept plus folfiri as third-line treatment after irinotecan 
containing regimen (XELIRI) which was not recommend for use by NCCN treatment 
guidelines for metastatic colorectal cancer (129). The study did not found any form of 
off-label use of aflibercept either as single agent or in combination with drugs other than 
FOLFIRI for the treatment of metastatic colorectal cancer. The efficacy of the 
aflibercept in this study based on the median PFS (5.9 vs 6.9 months) and median OS 
(15 vs 13.5 months) was comparable with VELOUR study (93). A retrospective analysis 
for aflibercept under SAP in Malaysia found that aflibercept was well-tolerated and 
efficacy in terms of PFS was 6.12 months and OS was 12 months (162). They also found 
that 12% patients received aflibercept plus folfiri in off-label manner in first-line 
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treatment setting. The main serious toxicity observed was proteinuria and febrile 
neutropenia. A meta-analysis found that aflibercept carries an increased risk of high 
grade proteinuria in cancer patients with a cumulative incidence rate of 7.9 % (95% CI; 
6.1–10.2) (163). The exact mechanism regarding aflibercept mediated proteinuria is yet 
to be established. Higher grade febrile neutropenia was more frequent with aflibercept 
plus folfiri (4%) than folfiri alone (2%) in the VELOUR study (93). Although the 
incidence for serious toxicity is low in the study population, the treating oncologist 
should be aware of potential serious side-effects and provide appropriate interventions to 
patients. 
 
There are myriad of studies which have estimated off-label of anti-cancer drugs in 
routine practice (49, 63-67). Off-label prescribing of anticancer medicines under SAP is 
rarely reported. A Canadian study surveyed oncologists at a major academic hospital on 
use of enzalutamide in metastatic castrant-resistant prostate cancer under the SAP (164). 
The survey was completed for patients treated with enzalutamide by the oncologists. 
Enzalutamide which was approved for the post-docetaxel setting was given in off-label 
manner before the exposure to docetaxel in 65% of total patients. Out of 65% patients 
treated in off-label manner, 46% patients were given enzalutamide as first-line before the 
trial data on efficacy and safety was even released. The one of the reasons cited by 
treating oncologists to use enzalutamide in off-label manner was availability of drug 
under the SAP and free availability. The drugs used under SAP are provided by 
pharmaceutical companies without charging the patients. Hence, there is almost no 
reimbursement constraint for off-label prescribing of oncology products as experienced 
in routine practice (39). A recent study in Spain assessed the off-label use of 
bevacizumab which is also a potent angiogenesis inhibitor (165).  In this retrospective 
observational study among 226 cancer patients, 43% of treatment episodes for 
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bevacizumab were off-label mainly due to unapproved indication (35 episodes) and 
unapproved line of treatment (31 episodes).  
 
The investigational drug use under SAP are becoming increasingly controversial (166). 
Every year thousands of cancer patients are getting treated under expanded or 
compassionate access programs across the world (167-174). The main concern is that the 
drug is only approved for specific indication or line of treatment and off-label use for 
clinical situations where reliable statistics didn’t exist could jeopardize patient safety. 
Because the newer agents or even combinations could have unexpected toxicity risk in 
the treatment setting outside the approved recommendations. For example, combination 
of ipilimumab and vemurafenib, both being potent BRAF inhibitor resulted in increased 
hepatotoxicity. This signifies that even though both agents are regulatory approved for 
the treatment of advanced melanoma, the requirement of clinical trial  data is highly 
necessary for novel off-label use (175). The same concern over efficacy for the off-label 
drug use in SAP exists. If there is not enough evidence, either quality of life or survival 
should improve. For example, no practice setting should allow use of sorafenib as 
adjuvant therapy in hepatocellular carcinoma as it doesn’t improve survival or quality of 
life irrespective of patients’ wish or willingness to pay (176, 177). 
 
There are factors related to patients and treating oncologists that could lead to off-label 
prescribing in SAP. As patients sometimes might misunderstand that chemotherapy 
could cure their cancer and be convinced to try a new drug as ‘last hope’  outside the trial 
conditions (178). Recently, a survey found that terminally ill patients in hopes of gaining 
access to experimental therapeutics are increasingly using social media and online 
petitions and majority of them are cancer patients (179). On the other hand, oncologists 
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have limited guidance on when to stop systematic chemotherapy in advanced cancers, 
especially in those who have exhausted approved drugs and lines of treatment (180). 
Also, oncologists are ethically obliged to offer the option of investigational drugs, but it 
might come at the cost of reduced trial participation (181). But we should bear in mind 
that in the context of life threatening disease like cancer, effective palliation may be 
undermined if patients are led to believe that the new experimental drug is their “last 
hope”. This lost opportunity is a real harm that must be considered in any risk-benefit 
calculation (182).  
 
The main limitation of the study was that the study has small sample size and focused on 
one drug only. Also this was a single centre study and hence, it is difficult to extrapolate 
the results. There should be more research on the appropriateness of drug use under SAP 




The study found the use of aflibercept outside the approved treatment regimen in 
metastatic colorectal cancer patients. The clinical place of aflibercept in the treatment of 
metastatic colorectal cancer would continue to be informed by future practice trends and 
new clinical trial data. This finding of providing the evidence of off-label prescribing in 
SAP is preliminary and requires further investigations as the impact of treatment on 






4 Perception of oncology practitioners towards off-label use of anticancer medicines  
4.1 Introduction 
Off-label drug use applies when drugs are used for indication, dosage, route of 
administration or patients population that are different from those mentioned in their 
prescribing information (1). Such off-label drug use is particularly common in the field 
of cancer therapy, where there is a substantial unmet medical requirement, the variety of 
patient populations and a constellation of rare tumour types which together make 
standard therapy protocols more difficult to apply. Hence, off-label prescribing is an 
indispensable practice to provide patients what is necessary for their medical care based 
on the premise of available scientific evidence (49, 63-66, 183).  
 
However, several concerns make off-label use of anti-cancer medicines controversial. 
Scientific evidence guiding the off-label prescribing is frequently inadequate.  Coupled 
with uncertain clinical, humanistic and economic outcomes, a clinical judgement to 
prescribe off-label drugs may be sub-optimal in many clinical scenarios (184). All these 
concerns heightened the reason to understand practice concerning off-label drug use 
from the oncology practitioners’ perspective. The previous study in the US reported 
significant variation in practice and attitudes among oncologists regarding such practice. 
The lack of consensus among oncologists could be a potential reason for variable drug 
access to patients with similar medical conditions (41, 185). Moreover, the non-medical 
oncology practitioners including nurses and pharmacists also play very significant role in 
cancer care. Oncology nurses provide patient services through different roles and clinical 
setting, such as nurse-run treatment centres, chemotherapy pre-screening, chemotherapy 
administration, manage symptoms and providing psychosocial support. They play vital 
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supportive roles in the treatment decisions and in improving communication between the 
clinicians and other members of the patient’s healthcare team (186, 187). On the other 
hand, oncology pharmacists have to fulfil the roles of patient advocates and drug 
information specialists. Pharmacists could query and intervene off-label prescriptions 
containing anti-cancer drugs with insufficient evidence for efficacy and safety (188). As 
such, the views of nurses and pharmacists on off-label drug use are also critical.     
 
Increasingly, oncologist practitioners are positioned under the professional and ethical 
code of conduct and responsibilities ensuring rationale drug use practice. Hence, the 
knowledge of their perceptions pertaining to off-label prescribing in cancer therapy is 
necessary. Currently, the oncology practitioners’ perceptions on practice of off-label 
chemotherapy use and issues pertaining to lack of efficacy, unfavourable benefit-risk 
ratio, economic burden and informed consent for patients are not well documented. This 
study, therefore, attempted to document the perceptions of oncology practitioners 
regarding off-label drug use practice at the largest ambulatory cancer centre situated in 
Singapore. The study also compared perceptions regarding off-label drug use between 




The National Cancer Centre (NCC) is one of the three public institutional centres for the 
diagnosis, treatment and research of cancer in Singapore. The NCC works across three 
main domains of cancer care, research, and education. NCC provides clinical services 
through its five clinical divisions (medical oncology, surgical oncology, radiation 
oncology, oncologic imaging and palliative care). There are three separate research 
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departments; clinical trials and epidemiological sciences, medical sciences and cellular 
and molecular research. The NCC delivers education to the general population, students 
from the three medical institutes in Singapore, local and overseas resident fellows, as 
well as, post-graduate research scholars. It currently treats 70% of government 
subsidized cancer  patients and 50% of all patients in the island nation (189). 
 
4.2.2 Study design 
This was a cross-sectional survey-based research study conducted between November 
2015 and January 2016. We attempted to gather maximum responses within the sample 
oncology practitioners working at the NCC. All medical oncologists (n=37), oncology 
trained nurses (n=36), and pharmacists (n=22) working at NCC were invited to 
participate in the study. Based on the information regarding oncology practitioners 
working at NCC, a total of 95 questionnaires were prepared for distribution. All the 
participants completed the survey questionnaire by pen and paper mode.  The completed 
surveys were received after a one-month period. The survey did not contain any personal 
information that could potentially specify the identity of a particular participant. The 
questionnaire was written in English and required about 20 minutes for self-
administration. The study was reviewed and approved by the Singhealth Institutional 
Review Board.  
 
4.2.3 Survey design 
The questionnaire (Appendix I) was developed after extensive literature review. A panel 
consisted of medical oncologists, oncology pharmacists, advanced practice nurses and 
academic pharmacists, examined the research instrument for face and content validity. 
 58 
 
Criterion validity was not determined due to the absence of existing validated surveys. 
Pilot work was performed by three medical oncologists, three nurses and three 
pharmacists. Subsequently, questions were adjusted as appropriate for clarity and 
understanding before conducting the actual study. The questionnaire principally 
concentrated on off-label drug use in cancer therapy and consisted of three main 
segments. The first segment focused on explaining the objective of the study and 
information concerning the definition of off-label drug use. Several examples were 
provided to explain the terms for participants who might not be aware of the 
terminology. The second part described demographic details and information about each 
oncology practitioner’s clinical experience including age, gender, profession, years of 
practice in oncology, patient load, and time spent on direct patient care. The third section 
was designed to capture perceptions regarding the practice of off-label drug use with an 
emphasis on the use of scientific evidence, expected efficacy, safety concerns, informed 
consent and out-of-pocket cost issues.  
 
4.2.4 Data analysis 
The information regarding participants’ demographic and clinical practice is shown as 
frequencies and percentages.  The responses on Likert scale (survey questions numbered 
1, 9 and 12) were dichotomized into two categories. “Strongly agree” and “Agree” were 
categorized as “agree”, while “Strongly disagree”, “Disagree” and “Neutral” were 
categorized as “disagree” (190). To facilitate the analysis for group comparison, the non-
medical practitioners included the nurses and pharmacists. Statistics such as Chi-square 
or Fischer exact test were employed to measure significant variances between two 
groups. The variables for multivariate regression analysis were selected based on the 
value of variance inflation factor (VIF < 3) as measure of multicollinearity and adequate 
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number of participants for each sub-category. Multivariate logistic regression was 
performed to adjust for potential confounding effects (such as age, gender, years of 
practice in oncology, patient load, time spent on patient care and profession). The effect 
size of the bivariate associations was represented as crude and adjusted odds ratio (OR).  
A two-tailed p-value of less than 0.05 was considered statistically significant. Statistical 
analyses were performed using Statistical Package for Social Sciences version 22 (SPSS 
Inc. Chicago, IL). 
 
4.3 Results 
4.3.1 Demographics  
A total of 81 survey questionnaires were returned, providing a response rate of 85% (81 
responses out of 95 practitioners). Among the surveyed oncology practitioners, the 
majority of them were nurses (38%) and medical oncologists (37%). The majority of the 
participants were females (n= 59; 73%) and aged between 31 and 40 years old (n= 33; 
41%). Majority of medical oncologists (n= 23; 76%) and nurses (n=21; 67%) have 
practice experience in oncology of more than 6 years. Overall, 64% participants on 
average had a patient load of at least 100 cancer patients per month. Majority of medical 
oncologists (n=21; 69%), pharmacists (n=17; 85%) and nurses (n=28; 89%) reported 
spending minimum 40 hours of their time on direct patient care per week. The detailed 






















Age (years)       
20 - 30  22 (27)  02 (07) 10 (50) 10 (32) 
31 - 40  33 (41)  11 (36) 07 (35) 15 (48) 
>40  26 (32)  17 (57) 03 (15) 06 (18) 
Gender       
Male  22 (27)  19 (64) 03 (15) 00 (00) 
Female  59 (73)  11 (36) 17 (85) 31 (100) 
Years of practice in oncology        
<02   12 (15)  04 (14) 03 (15) 05 (16) 
02 – 05   19 (24)  03 (10) 11 (55) 05 (16) 
06 – 10   28 (34)  12 (40) 05 (25) 11 (35) 
>10  22 (27)  11 (36) 01 (05) 10 (32) 
Patients load per month        
21 - 50  09 (11)  05 (16) 01 (05) 03 (09) 
51 – 100  20 (25)  06 (19) 04 (20) 10 (32) 
101 – 150  19 (23)  06 (19) 03 (15) 10 (32) 
>150  33 (41)  13 (45) 12 (60) 08 (26) 
Time spent on patients care per 
week (hours) 
<40 






























in last one month 
      
<05  38 (47)  20 (64) 04 (20) 14 (45) 
06 – 10  24 (30)  04 (14) 08 (40) 12 (38) 
11 - 20  11 (13)  02 (07) 07 (35) 02 (06) 
>20  08 (10)  04 (07) 01 (05) 03 (09) 
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4.3.2 The practice of off-label drug use in oncology.  
Majority of the surveyed oncology practitioners (77%) encountered maximum ten 
prescriptions containing off-label use during last one month of clinical practice. Off-
label drug use was considered to be integral practice in cancer therapy by 57% of the 
participants. Off-label drug use was reported to be most common in palliative (67%) and 
adjuvant care (49%), followed by neoadjuvant (48%) and curative setting (38%) as 





≠Rank 1: Most common, Rank 4: Least common. 
 






















































≠Rank 1: Most common, Rank 4: Least common. 
 
Figure 4 Reported categories of off-label drug use. 
 


























Advanced stage of disease where other lines of 
treatments are exhausted. 
 
 
47 (58) 19 (63) 14 (70) 14 (45) 28 (55) 0.46 
Rare oncologic conditions.  38 (47) 16 (53) 13 (65) 09 (29) 22 (43) 0.38 
No approved agents for disease.  35 (43) 15 (50) 14 (70) 06 (19) 20 (39) 0.34 




33 (41) 16 (53) 13 (65) 04 (13) 17 (33) 0.08 




25 (31) 04 (13) 13 (65) 08 (26) 21 (41) 0.012 
Lack of trial availability at the institution.  18 (22) 12 (40) 04 (20) 02 (06) 06 (12) 0.003 




17 (21) 07 (23) 06 (30) 04 (13) 10 (20) 0.69 
*The numbers may not add up to the total number of participants due to missing data. The p-value was calculated 
using the chi-square test or Fischer exact test as appropriate. The p-value is indicative of significance between medical 
oncologists and non-medical practitioners (pharmacists and nurses combined). 
 
 
Among different categories of off-label drug use percieved to be practised, modified 
drug applications (34%), unapproved line of treatment (37%) were the most common 



















































therapeutic intent (32%) as shown in Figure 4. The reasons and evidence base for off-
label drug use are summarised in Tables 9 and 10. Major reasons cited by the 
participants were failure of standard lines of treatment in advanced stage of cancers 
(58%), rare tumours (47%), lack of approved drugs for particular cancer indication 
(43%) and sound evidence of supporting efficacy and safety of off-label drug use (41%).  
 
However, off-label drug therapy having better efficacy than standard therapy was 
perceived as the more compelling reason for off-label prescribing by non-medical 
practitioners than medical oncologist (41% vs.13%, p=0.012). On the contrary, medical 
oncologists considered the lack of clinical trial availability at the institution as one of the 
reasons for off-label prescribing compared to non-medical practitioners (40% vs. 12%, 
p=0.003). Patient refusal or ineligibility for trial (21%) was the least convincing reason 
for off-label use in cancer therapy.  
 
Table 10 Reported use of different evidence base for off-label prescribing (n=81). 
 
 






















        
Data from Phase 3 randomised control trial.  56 (69) 26 (86) 17 (85) 13 (42) 30 (59) 0.12 




54 (66) 23 (76) 16 (80) 15 (48) 31 (61) 0.14 
Meta-analysis of randomised control trials.  48 (59) 20 (66) 13 (65) 15 (48) 28 (55) 0.30 
Data from Phase 2 clinical trial.  38 (47) 22 (73) 09 (45) 07 (22) 16 (31) 0.001 




29 (36) 17 (56) 08 (40) 04 (13) 12 (23) 0.003 
Meta-analysis of observational studies.  25 (31) 09 (30) 06 (30) 10 (32) 16 (31) 0.89 
Well conducted observational studies.  14 (28) 05 (16) 02 (10) 07 (22) 09 (17) 0.91 
Case report or Case series.  19 (23) 07 (23) 03 (15) 09 (29) 12 (23) 0.98 
Drug compendia information.  13 (16) 03 (10) 07 (35) 03 (09) 10 (19) 0.35 
*The numbers may not add up to the total number of participants due to missing data. The p-value was calculated 
using the chi-square test or Fischer exact test as appropriate. The p-value is indicative of significance between medical 




The majority of oncology practitioners supported off-label use based on Phase 3 
randomized control trial (69%), treatment guidelines, such as NCCN (66%) and meta-
analysis of randomised control trial (59%). It was found that medical oncologists would 
consider phase 2 trial data (73% vs. 31%, p=0.001) and conference abstracts (56% vs. 
23%, p=0.003) as reasonable evidence for off-label drug prescribing than non-medical 
practitioners.  Evidence from observational studies (28%), case reports or series (23%) 
and drug compendia (16%) were the least preferred reasons by oncology practitioners.  
 



































       
Lack of efficacy 19 (63)  14 (70) 14 (45) 28 (55)  0.90 
Patients understanding 16 (53)  13 (65) 09 (29) 22 (43)  0.08 
Questionable Safety 15 (50)  14 (70) 06 (19) 20 (39)  0.47 
Out-of-pocket cost 16 (53)  13 (65) 04 (13) 17 (33)  0.004 
Insufficient scientific evidence 04 (13)  13 (65) 08 (26) 21 (41)  0.02 
No Informed consent 12 (40)  04 (20) 02 (06) 06 (12)  0.33 
Legal liabilities 07 (23)  06 (30) 04 (13) 10 (20)  0.06 
*The numbers may not add up to the total number of participants due to missing data. The p-value was calculated 
using the chi-square test or Fischer exact test as appropriate. The p-value is indicative of significance between medical 
oncologists and non-medical practitioners (pharmacists and nurses combined). 
 
4.3.3 Concerns with off-label drug use 
The main concerns with off-label use in cancer therapy are described in Table 11. 
Among the oncology practitioners, lack of efficacy (58%), patients understanding (47%) 
and drug safety (43%) were the top concerns with the practice of off-label drug usage. 
Medical oncologists were more concerned about out-of-pocket cost (53% vs. 33%, 
p=0.004) than non-medical practitioners. On the other hand, non-medical practitioners 
stated to be more apprehensive with insufficient scientific evidence supporting off-label 
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use (41% vs. 13%, p =0.02) than medical oncologists.  Lack of informed consent (22%)  
and legal liabilities (21%) were the additional concerns expressed. Overall, more than 
half of the oncology practitioners (58%) stated to have experienced adverse events wi th 
off-label drug use.  
4.3.4 Recommendation with off-label drug use in routine clinical practice 
The expected outcomes and recommendations for off-label drug use practice are 
represented in Table 12.  There was no consensus regarding survival benefit among 
oncology practitioners. Higher survival benefit of six months was more endorsed by 
non-medical practitioners (37% vs. 13%, p=0.02) than medical oncologists. Of all the 
oncology practitioners, 59% of the participants agreed upon moderate improvement in 
the quality of life of cancer patients with off-label drug use.  Among all, discussion 
about off-label use with patients (71%), obtaining informed consent (86%) and 
institutional level guidance (75%) were highly recommended. On multivariate analysis 
as shown in Table 13, none of the variable was found to be significantly associated with 
perceived importance of off-label drug use in cancer therapy among different oncology 
practitioners. 






















        
1-3 months survival benefit 23 (28)  11 (39) 05 (20) 07 (22) 12 (23) 0.22 
4- 6 months survival benefit 23 (28)  11 (39) 05 (20) 07 (22) 12 (23) 0.22 
More than 6 months survival benefit 23 (28)  04 (13) 09 (45) 10 (32) 19 (37) 0.02 
Slight improvement in overall quality of life 16 (19)  04 (13) 04 (20) 08 (26) 12 (23) 0.38 
Moderate improvement in overall quality of life 41 (59)  17 (56) 10 (50) 14 (44) 24 (46) 0.40 
Significant improvement in overall quality of life 22 (27)  09 (30) 06 (30) 07 (22) 13 (25) 0.66 
Discussion with patients about off-label use 58 (71)  19 (63) 15 (75) 24 (77) 39 (76) 0.20 
Obtaining informed consent from patients 70 (86)  28 (93) 12 (60) 30 (97) 42 (82) 0.16 
Need for Institutional level guidance 61 (75)  20 (66) 17 (85) 24 (77) 41 (80) 0.25 
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*The numbers may not add up to the total number of participants due to missing data. The p-value was calculated 
using the chi-square test or Fischer. The p-value is indicative of significance between medical oncologists and non-
medical practitioners (pharmacists and nurses combined). 
 
































































Years of practice in oncology 
>10 
06 - 10 
















































































As far as our knowledge is concerned, this is the first original survey research done 
within Asia to gather oncology practitioners’ perceptions on the practice of off-label use 
in cancer therapy. The benefit of this important evidence would ensure the design of 
suitable clinical guidance and education strategies for the oncology community. The 
majority of the oncology practitioners recognised the fact that off-label drug use is 
integral and common practice in cancer pharmacotherapy. Off-label drug use was 
perceived to be practised across almost all types of chemotherapeutic regimens and 
therapeutic intents. However, the majority of participants acknowledged their concerns 
over the lack of efficacy, uncertain safety, increased out-of-pocket costs and ethical 
issues pertaining to patients’ understanding and informed consent. 
 
The prevalence of off-label prescribing in this study is self-reported by the participants 
which might not relate to the findings based on the assessment of drug prescriptions.  
This discordance between self-perceived prevalence and prescriptions could be 
explained due to the fact that healthcare professionals sometimes do not correctly 
identify a drug’s FDA approval status for a particular indication at the time of 
prescribing, administering or dispensing (60). The main reported therapeutic intent for 
off-label drug use was palliative care. This finding is consistent with previous studies 
which reported off-label drug use being prominent in advanced cancers (52, 66, 68). The 
second common goal for off-label drug use was adjuvant setting where the objective of 
the therapy is to prevent reoccurrence of tumour once it is surgically removed. Drugs 
which are found to be active in metastatic disease are often used in an adjuvant setting in 
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an off-label manner. A drug may exhibit altered benefit-risk profiles in differing settings 
for the same cancer type. For example, in colorectal cancer, many drugs (including 
bevacizumab) with proven efficacy in the metastatic setting but have failed to improve 
outcomes in the adjuvant treatment (191). Despite this lack of clinical benefit, 
bevacizumab is still being prescribed in the adjuvant setting in colorectal cancer (73, 74).  
 
Similarly, drugs approved in adjuvant setting are used in neo-adjuvant setting as in the 
case of breast cancer surgery where pertuzumab is the only regulatory approved drug 
(63, 64, 66, 67, 73, 192, 193). Modified drug application was the most common category 
of off-label use which could be explained mainly due to lack of available dosage forms 
or combination agent, drug allergies, co-morbidities, organ functions etc. (66, 75, 80). 
While the unapproved line of treatment was perceived to be second common category 
pertaining to off-label drug use due to use of approved drugs beyond specified number of 
lines of treatment and also due to continuing use of treatment beyond disease 
progression in advanced cancers. For example, use of trastuzumab in off-label manner 
beyond disease progression in patients with metastatic breast cancer (78). Off-label drug 
use was also reported for unapproved indication which could be explained due to lack of 
FDA approved drugs for rare tumours or diagnosis of cancer with specific genetic 
mutations (58, 151). 
 
Many participants reported that off-label drug use could be considered when it is better 
than standard therapy or had strong evidence to support the practice. This attitude could 
be explained by the fact that clinical trials could not guide every prescription in routine 
practice and off-label use based on evidence-based approach is necessary (61). One such 
example has been observed in local setting where attenuated dosing of sunitinib yielded 
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comparable efficacy and reduced toxicity than the regulatory approved regimen (194). 
But in many cases, off-label drug use has become standard care. For example, a 
combination of ifosfamide and etoposide for Ewing’s sarcoma for primitive 
neuroectodermal tumour of the bone and paediatric cancers (195).  The participants 
perceived that lack of clinical trial availability and patients’ refusal or ineligibility to 
recruit as less convincing reasons for off-label drug use. The previous study found that 
oncologists were reluctant to offer off-label therapies to those patients who refused to 
participate in the trial and agreed that patients should be discouraged from experimental 
drug use outside trials (185). It is also reported that access to experimental therapies 
outside trial in the form of off-label drug use could also potentially limit trial recruitment 
and impact the accumulation of gold standard evidence (181). Non-medical practitioners 
were less likely to recommend off-label use based on phase 2 trial data and conference 
abstracts. But medical oncologists might consider it appropriate for cancers with specific 
genetic alterations or treatment of rare tumours where large scale trials are difficult to 
conduct (75, 151). Drug compendia were least convincing evidence and studies found 
them as not reliable because lack of transparency in their review process for the off-label 
indication in oncology (196).  
 
Lack of efficacy and questionable safety with off-label drug use were the key concerns 
with off-label drug use. Off-label chemotherapies without sound scientific evidence 
would not provide any meaningful clinical benefit but potentially expose patients to the 
risk of toxicities and increase treatment costs (50, 63, 197).  A 20% rate of hepatic 
sinusoidal obstructive syndrome was noticed when gemtuzumab, a drug approved as 
single agent for acute myelogenous leukaemia, was prescribed as an off-label 
chemotherapy treatment in combination with thioguanine (35). Recently, the first ever 
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randomised control trial designed to study clinical outcomes with off-label drug use 
versus standard regimen found that off-label drug use provided no clinical advantage 
(198). The perceived toxicity concern might be attributed to inadequate information 
about off-label drug use regarding dosing guidelines, contraindications, drug interactions 
and side-effects profile. Hence, non-medical practitioners would certainly face 
difficulties in drug compounding, administration, and patient counselling activities. 
Moreover, the information on off-label drug use is poorly disseminated among 
healthcare professionals (196, 199).  
 
Medical oncologists were more concerned regarding out-of-pocket cost as they usually 
participate in the decision-making process for off-label use and discuss cost issues with 
patients. This might be explained by the fact that the national insurance policy 
(MediShield Life) in Singapore has a maximum claimable limit of S$3000 per calendar 
month for selected chemotherapy (200). Likewise developed countries such as USA and 
Australia, many insurance companies denied reimbursements for off-label indications to 
treat cancer on the ground that these uses are "experimental" or "investigational” thus 
increasing patients out-of-pocket costs (39, 201).   
 
The participants reported their concerns regarding patients understanding and informed 
consent with off-label drug use. This might be attributed to the misconceptions among 
patients regarding treatment intent of chemotherapies in advanced cancers which often 
lead to the demand of drugs access beyond approved usage (178, 180, 202). As a 
recommendation, patients should be properly educated about every off-label drug use, 
supporting evidence, the risk of toxicities and financial impact on treatment costs (43, 
203). Obtaining informed consent was highly recommended by participants to safeguard 
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patient autonomy leading to better healthcare decision with off-label use and  to prevent 
any future legal liabilities (204). The oncology practitioners had a general consensus on 
moderate enhancement in the overall quality of life than specific survival  gains with off-
label drug use and these findings are consistent with previous studies with similar 
objective (205). The need for robust practice framework and clinical guidance was 
highlighted by participants as a necessity to facilitate judicious off-label prescribing and 
it could be similar to those suggested by Australian guidelines (29) A collaborative 
practice model among oncology practitioners could assist with evidence-based off-label 
prescribing and support best practice standards (71, 206-208).  
 
This research study has some limitations. “Self-reported” surveys have drawbacks with 
respect to accurately evaluating prescribing, dispensing and drug use practice. The 
survey questionnaire depends on participants’ self-administration, which may provide 
responses that are appealing to the researcher rather than indicating what the participant 
actually considers. To reduce self-reporting bias, the confidentiality of the participants 
was confirmed and clarified to the participants. There is also the probability of recall 
bias. An effort to reduce this factor was carried out, i.e. by restricting the period of recall 
to 1 month. Our sample consisted of heterogeneous oncology practitioners (medical 
oncologist, nurses and pharmacist). Future studies with one group of oncology 
practitioners or qualitative studies on patients and caregivers are recommended to gather 
their insights. Our survey was also Singapore specific, but given that such issues are 
international, our results should be of interest to healthcare professionals in other 
countries particularly in Southeast Asia. Moreover, we did not consider paediatric 
oncology which is also an important area and has its own implications for off-label drug 
use that need to be addressed by similar studies in future (209). As such, the present 
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study should be regarded as an effort to gather general views on this important issue and 
should not be interpreted as sole evidence on any aspect of this issue. 
 
4.5 Conclusion 
Off-label drug use in cancer care is considered to be important by oncology practitioners. 
However, they expressed several concerns such as lack of efficacy, safety, and costs that 
need to be adequately addressed. Findings from the study also suggested the need for 
patient involvement in the decision-making process, the consideration for clinical 
guidance and educational strategies at institution level to facilitate judicious practice to 














5 Future Directions  
Off-label drug use in oncology is here to stay as it is not possible to do clinical trials for 
each and every prescription and getting regulatory approvals for it.  However, the whole 
system could be structured to maximize the likelihood of a favourable benefit – risk ratio 
for patients under robust clinical governance guidelines which can work across all the 
care settings, prescribing, supply, administration, and reimbursement.  
 
The data on the prevalence of off-label use of anti-cancer drugs in Singapore is 
unknown.  A population-based cohort study determining the prevalence of off-label use 
of anti-cancer drugs is needed. It would be also prudent to assess cost component 
associated with off-label drug use. For those off-label uses where the evidence is limited, 
it is highly necessary to study their efficacy and safety to guide future prescribing.  As 
off-label drug use is often demanded by patients, qualitative surveys to know their 
insights regarding off-label use would help to understand and strengthen the ethical basis 
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7 Appendices                                    
7.1 Appendix I 
Questionnaire 
“Perception of Oncology practitioners towards off-label use of anticancer 
medicines” 
Health Science Authority (HSA) is the drug regulatory body of Singapore. HSA Drug 
regulatory body approves a drug for use in clinical practice based on controlled studies 
and strict licensing criteria. HSA also publishes the label for each drug providing 
guidance to clinical practitioners for its clinical use. Off-label use is defined as the use of 
drug which is not consistent with the regulatory label. In oncology, off-label use is 
common and could be classified into different categories. They include unapproved 
indication, unapproved line of treatment, unapproved intent of treatment or unapproved 
modification of dose. Specific examples are given below. 
 
Off-label category Example 
Unapproved indication Oxaliplatin is a drug approved for colorectal cancer but used in breast 
cancer 
Unapproved line of treatment Panitumumab is used as first line therapy instead of treatment of pre-
treated metastatic colorectal cancer 
Unapproved intent of 
treatment 
Use of irinotecan in the adjuvant setting instead of metastatic colorectal 
cancer 
Unapproved modification of 
dose 
High dosing of carboplatin in intensive chemotherapies instead of 
approved dose 
*Ref: Leveque, Dominique. "Off-label use of anticancer drugs." The lancet oncology 9.11 (2008): 1102-
1107 
 
Demographics of respondent 
 
1. Age (years) 
 20 – 30     31 – 40
  
 41 – 50      51 – 60      > 60 
2. Gender   
 Male     Female    
 
3. Profession 
 Medical Oncology  
 Surgical Oncology  
 Radiation Oncology  
 Pharmacist       
 Nurse 
 
4. Years of practice in Oncology 
 < 2  2 – 5  6 – 10  > 10  
 87 
 
5. Patient load per month  
 < 20  21 – 50  51 – 100   101 – 150  > 150 
6. Time spent on direct patient care per week (hours) 
 < 40  40 – 60  > 60 
 
  
1. Off-label use of cancer therapies are integral part of oncology practice.  
 Strongly 
Agree  





If agree, please give reason(s). (Tick ALL that apply) 
 Advanced stage of disease where other lines of treatments are exhausted. 
 No approved agents for disease. 
 Rare oncologic conditions. 
 Sound evidence of efficacy and safety for off-label prescription. 
 Off-label therapy show better efficacy than standard therapy. 
 Lack of trial availability at the institution. 
 Patients refuse to enter clinical trial or are ineligible for them. 
 Others: 
 
2. What type of evidence constitutes appropriate off-label anticancer drug use? (Tick 
ALL that apply) 
 Case report or case series 
 Well conducted observational studies 
 Meta-analysis of observational studies 
 Data from Phase 2 clinical trials 
 Data from Phase 3 randomised control trials 
 Meta-analysis of randomised control trials 
 Drug compendia information 
 Off-label use included in treatment guidelines, such as NCCN 
 Conference abstracts of reputed meetings, such as ASCO or ESMO 
 
3. In your opinion, which is the most common category of off-label use? Please rank 
on a scale of 1 to 4 where 1 is the most common and 4 is the least common.  
 
Categories of off-label use 
  Indication 
  Line of treatment 
  Intent of cancer therapy (neoadjuvant, curative, adjuvant and palliative) 








4. In your opinion, which is the most common therapeutic intents for off –label drugs 
use in cancer patients? Please rank on a scale of 1 to 4 where 1 is the most common and 
4 is the least common.  
 






5. How often did you prescribe/dispense/administer off-label drugs in the last 1 month? 
 Less than 5 prescriptions  10-20 prescriptions 
 5-10 prescriptions  More than 20 prescriptions 
  
6. What are your main concerns when you prescribe/dispense/administer off-label 
medicines? (Select the top 3 concerns) 
 Lack of efficacy  Patients’ understanding 
 Questionable Safety  Legal liabilities 
 Insufficient scientific evidence  Cost to patients 
 No Informed consent  Others:____________________ 
 
7. In your opinion, what should be a clinically meaningful outcome from use of off-label 
anticancer medicine?  
A. Survival benefit (Tick one option only) 
 1-3 months  4-6 months  More than 6 months     
 Survival benefit is not a consideration at all 
B. Quality of life (Tick one option only) 
 Slight 





 Quality of life is not a consideration at all 
 
8. Have you ever encountered any adverse drug events (ADR) when you prescribe/ 
dispense/administer off-label anticancer medicines? 
 Yes  No 
If yes, which type of ADR? 
 Mild  Moderate  Severe or life threatening 
 
9. It is a good practice to discuss off-label use with patients/caregivers while making 
medical decisions.  
 Strongly 
Agree  






10. Should informed consent be obtained from patients when prescribing off-label 
anticancer medicines?  
 Yes  No 
If yes, please specify the mode. 




11. In your opinion, do you think that off-label use of anticancer medicine would increase 
out-of-pocket cost to patients? 
 Yes  No 
If yes, please provide reasons ………………………………………………….. 
  
12. There should be more institutional guidance to facilitate safe use of off-label drug use 
for the patients who need it. 
 Strongly 
Agree  














































7.2 Appendix II          
Data Collection Form 
Baseline characteristics:  
Gender:      M/F         Patient’s age (yrs.) at diagnosis:     Patient’s age (yrs.) at start of 
treatment:     
Ethnicity:                         Chinese/Malay/Indian/Others      
Date of Diagnosis:  Date of last follow-up:  Date of Death:  
_______________________________________________________________________________________________ 
 Disease characteristic:   
Primary site of cancer:         
If patient has multiple primaries, indicate additional sites:  
Stage of Cancer:   I/II/I/IV  
Metastatic phase at diagnosis :      Yes /No 
Metastatic site (s):  
ECOG Performance Status:                 at start of previous chemotherapy                     at start of unregistered use  
______________________________________________________________________________________________  
Prior Treatment for Cancer 
Received radiation therapy:              Yes /No. 
Received surgical treatment:  Yes/No 
Total number of prior chemotherapy regimens:    1
st
 line,               2
nd
 line,                > 3
rd
  
Details of previous chemotherapy:   
   
Stage of Disease at start of unregistered drug use :       1: No evidence of progression, 2: Disease progression, 
3:  stable disease, 4: unknown    
Localisation of Relapse: localized/metastatic/both 
Current treatment for cancer 
Unregistered Drug name: 
Intent of unregistered drug use : Curative/Adjuvant/Neoadjuvant/Palliative  






 or more 
Concomitant chemotherapy with unregistered drug: Chemotherapy Only/targeted therapy/ Chemotherapy + 
targeted therapy 
Unregistered chemotherapy start date : 





Date of last unregistered drug use:  
Last date of supply for oral unregistered drug use: 
No. of cycles of unregistered drug administered: 
Best clinical response:                CR/PR/SD/PD   [CR (Complete Disappearance of Lesions), PR (Partial Response), 
SD (Stable), PD (Progressive disease)] 
Visit and response reported:  
 
 
Reason for unregistered drug use discontinuation: 
 
Toxicities : Classified based on NCI Common Terminology Criteria for Adverse Events 
Type of toxicity Grade 1 (n) Grade 2 (n) Grade 3 (n) Grade 4 (n) 
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
 
